Treatment
By inhibiting the nomacopan-type protein of complement and LTB4 pathways, direct introduction or local administration into the eyes, the shortcomings of existing methods for treating proliferative retinal diseases are solved, effective reduction of VEGF levels and neovascular blockade are achieved, and a new type of protein is provided. treatment plan.
Patent Information
- Application Number
- CN202080046367.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-22
- Filing Date
- 2020-03-04
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-03-04
AI Technical Summary
Existing methods for treating proliferative retinal diseases have not yet fully met clinical needs, especially in terms of inhibiting retinal neovascularization and reducing visual loss, and previous complement inhibitors have failed to effectively penetrate the cornea and cannot be administered locally To treat intraocular lesions.
Nomacopan-type proteins are introduced directly or topically into the eyes by inhibiting complement pathways and LTB4 activity, binding to LTB4 but not C5, to reduce VEGF levels and reduce retinal neovascularization and permeability.
Effectively reduce the clinical scores of experimental autoimmune uveitis and proliferative retinal diseases, reduce the retinal VEGF levels, prevent the production and leakage of new blood vessels, and provide a new method for the treatment of proliferative retinal diseases, able to penetrate Permeate the cornea and act effectively in the eyes.
Smart Images

Figure CN114072206B_ABST
Abstract
Description
Field of the Invention
[0001] The present invention relates to methods for treating and preventing proliferative retinal diseases.
[0002] All documents mentioned herein and listed at the end of this specification are incorporated herein by reference. Background Art
[0003] Complement
[0004] The complement system is an essential part of the body's natural defense mechanism against foreign invasion and is also involved in inflammatory processes. More than 30 proteins in serum and at the cell surface are involved in the operation and regulation of the complement system. Recently, it has become apparent that in addition to the approximately 35 known components of the complement system that can be associated with both beneficial and pathological processes, the complement system itself interacts with at least 85 biological pathways with diverse functions such as angiogenesis, platelet activation and hemostasis, glucose metabolism, and spermatogenesis.
[0005] The complement system is activated by the presence of material recognized by the immune system as non-self. There are three activation pathways: (1) the classical pathway, which is activated by IgM and IgG complexes or by recognition of carbohydrates; (2) the alternative pathway, which is activated by non-self surfaces (lacking specific regulatory molecules) and by bacterial endotoxins; and (3) the lectin pathway, which is activated by binding of mannan-binding lectin (MBL) to mannose residues on the surface of pathogens. The three pathways involve the formation of C3-like ligands on the cell surface. 1 The C3a and C5 convertases lead to the release of acute inflammatory mediators (C3a and C5a) and the formation of the membrane attack complex (MAC), leading to a parallel cascade of events that results in complement activation. The parallel cascades involved in the classical (defined here as classical via C1q, and lectins via MBL) and alternative pathways are shown in Figure 1.
[0006] The classical complement pathway, the alternative complement pathway, and the lectin complement pathway are collectively referred to herein as complement pathways. C5b initiates the 'late' or 'terminal' events of complement activation. These include a series of polymerization reactions in which the terminal complement components interact to form MACs, which create holes in the cell membranes of some pathogens that can cause them to die, or activate the body's own cells without causing lysis. The terminal complement components include C5b (which initiates the assembly of the membrane attack system), C6, C7, C8, and C9.
[0007] LTB4
[0008] Leukotriene B4 (LTB4) is the most potent chemotactic and chemoactive eicosanoid described and promotes neutrophil adhesion to the vascular endothelium through integrin upregulation [1]. It is also a complete secretagogue of neutrophils, inducing their aggregation and increasing microvascular permeability. LTB4 recruits and activates natural killer cells, monocytes, and eosinophils. It increases superoxide radical formation [2] and regulates gene expression, including the production of a variety of proinflammatory cytokines and mediators that can enhance and prolong tissue inflammation [3,4]. LTB4 also plays a role in the induction and management of acquired immune responses. For example, it regulates dendritic cell trafficking to draining lymph nodes [5,6], Th2 cytokine IL-13 production from lung T cells [7], recruitment of antigen-specific effector CD8+ T cells [8], and activation and proliferation of human B lymphocytes [9].
[0009] LTB4 and hydroxyeicosanoids mediate their effects through the BLT1 and BLT2 G protein-coupled receptors [10,11]. Human BLT1 is a high affinity receptor specific for LTB4 (Kd 0.39-1.5 nM;
[12] ), of which only 20-hydroxy LTB4 and 12epi LTB4 are able to displace LTB4 in competitive binding studies
[13] . Human BLT2 has a 20-fold lower affinity for LTB4 than BLT1 (Kd 23 nM) and is activated by binding to a wider range of eicosanoids, including 12epi LTB4, 20-hydroxy LTB4, 12(S)- and 15(S)-HETE, and 12(S)- and 15(S)-HPETE
[13] . Human BLT2 shares 45.2% and 44.6% amino acid identity with human and mouse BLT1, respectively, while human and mouse BLT2 share 92.7% identity
[11] .
[0010] Human BLT1 is primarily expressed on the surface of leukocytes, but its expression in endothelial cells and vascular smooth muscle cells has recently been described. Human BLT2 is expressed in a wider range of tissues and cell types. A variety of specific antagonists of BLT1 and BLT2 have been described that inhibit activation, extravasation, and apoptosis of human neutrophils
[14] and reduce symptoms caused by neutrophil infiltration in mouse models of inflammatory arthritis
[15] and renal ischemia-reperfusion
[16] . An increasing number of studies indicate that both BLT1 and BLT2 can mediate pathological effects through LTB4 and hydroxyeicosanoids
[17] , but BLT1 certainly has a dominant role in some lesions, such as collagen-induced arthritis in mice
[18] . BLT1- / -deficient mice have also highlighted the importance of BLT1 in directing neutrophil migration in inflammatory responses. Specifically, the 5LO-deficient mouse strain was used to demonstrate that autocrine activation of BLT1 on neutrophils is required for recruiting neutrophils to arthritic joints
[19] .
[0011] A variety of commercially available drugs target eicosanoids. These include glucocorticoids, which regulate phospholipase A2 (PLA2) and thereby inhibit the release of the eicosanoid precursor arachidonic acid (AA)
[20] . Nonsteroidal anti-inflammatory drugs (NSAIDs) and other COX2 inhibitors that prevent the synthesis of prostaglandins and thromboxanes
[21] . There are also a variety of leukotriene (LK) modulators that inhibit the 5-LOX enzyme required for LTB4 synthesis and other leukotrienes (Zileuton;
[22] ), or antagonize the CysLT1 receptor that mediates the action of cysteinyl leukotrienes (Zafirlukast and Montelukast)
[23] . LK modulators are available orally and have been approved by the FDA for the treatment of, for example, asthma. There are no commercially available drugs that specifically act on LTB4 or its receptors.
[0012] Eye conditions
[0013] background
[0014] The present invention is directed to treating proliferative retinal diseases, which are retinal conditions involving the formation of blood vessels on the retina. For example, blood vessels may be generated in response to a reduction in blood supply caused by ischemia of the retina. This new angiogenesis generally occurs in response to the growth hormone vascular endothelial growth factor (VEGF), which stimulates the creation of new blood vessels on the optic disc or retinal surface. However, these new blood vessels are particularly weak, prone to leakage and can easily break, leading to bleeding and severe visual loss.
[0015] Such diseases include autoimmune uveitis, infectious uveitis, wet age-related macular degeneration (AMD) (choroidal neovascularization), dry age-related macular degeneration (geographic atrophy), diabetic retinopathy, diabetic macular edema, optic neuritis (e.g., glaucoma-related optic neuritis), retinal vein occlusion, and retinopathy of prematurity. Also included are Stargardt disease and polypoidal choroidal vasculopathy. Particularly relevant is uveitis.
[0016] There are currently treatments for some of these conditions. For example, in non-infectious uveitis, treatment focuses on controlling eye inflammation with anti-inflammatory drugs, such as steroids (e.g., corticosteroids) or immunomodulatory therapy (IMT) drugs (e.g., methotrexate, azathioprine, and mycophenolate mofetil), biological response modifiers (BRM) drugs (e.g., anti-TNFα agents, which can be antibodies or fragments thereof that bind TNFα, such as infliximab or adalimumab) given as eye drops, or injected in or around the eye, orally (perorally) or intravenously. For wet AMD, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy, current treatments include anti-VEGF therapy. These include anti-VEGF-A antibodies or fragments thereof (e.g., bevacizumab (Avastin), ranibizumab (Lucentis)), anti-VEGF aptamers (e.g., pegaptanib (Macugen)), and other VEGF antagonists, such as aflibercept (Eylea), a recombinant fusion protein consisting of the vascular endothelial growth factor (VEGF) binding portion from the extracellular domain of human VEGF receptors 1 and 2 fused to the Fc portion of a human IgG1 immunoglobulin). The anti-VEGF drug product can be injected intravitreally approximately every 1 to 2 months. These treatments have also been proposed for retinopathy of prematurity.
[0017] Proliferative retinal diseases remain an unmet clinical need.
[0018] Complement inhibitors
[0019] WO 2004 / 106369 (Evolutec Limited
[24] ) relates to complement inhibitors. A specific subset of the complement inhibitors disclosed is directed against C5 and prevents the cleavage of C5 into C5a and C5b via any of the complement activation pathways. A specific example of such an inhibitor of C5 cleavage is a protein produced by the tick species Ornithdoros moubata, the mature form of which is described in WO 2004 / 106369. Figure 4 The invention relates to a protein consisting of amino acids 19 to 168 of the amino acid sequence shown in WO 2004 / 106369. In WO 2004 / 106369, this protein is referred to as "rVA576", "EV576" and "OmCI protein" and more recently as "Coversin"
[25] . This protein is referred to herein as "nomacopan", which is the INN of the protein.
[0020] In ticks, nomacopan is expressed as a proprotein with a leader sequence comprising the SEQ ID NO: 1 at the N-terminus of the mature nomacopan protein as described in WO 2004 / 106369. Figure 4 The leader sequence is cleaved off after expression. The mature protein has the amino acid sequence of WO 2004 / 106369. Figure 4 and a sequence consisting of amino acids 19 to 168 of the amino acid sequence shown in Figure 2 of the present application.
[0021] Nomacopan also has the ability to inhibit the activity of leukotriene B4 (LTB4). The ability to bind LTB4 can be demonstrated by standard in vitro assays known in the art, such as competitive ELISA by competition between nomacopan and anti-LTB4 antibodies for binding to labeled LTB4, by isothermal titration calorimetry, or by fluorescence titration.
[0022] There are several additional patent applications, such as WO 2007 / 028968, WO 2008 / 029167, WO 2008 / 029169, WO 2011 / 083317 and WO 2016 / 198133, which relate to the use of nomacopan or its functional equivalents in various applications. There is no experimental evidence demonstrating the efficacy of nomacopan or any of its functional equivalents in the treatment of proliferative retinal diseases in these applications.
[0023] In studies prior to the present invention, the inventors have shown that the LTB4 receptor and the C5a receptor are co-located on cells within the retina of mice used in an experimental autoimmune uveitis model, in which disease is induced by injection of retinal binding protein (RBP3). At least some of these cells are believed to be M2 macrophages, which are known to migrate to areas of retinal damage, where they release VEGF in response to LTB4 stimulation. In addition, when injected into the vitreous, the molecule nomacopan (which binds LTB4 and also inhibits the complement pathway by binding to C5), as discussed above, and the long-acting form of nomacopan and LTB4-specific nomacopan (or "L-nomacopan", which binds LTB4 but does not inhibit the complement pathway by binding to C5), referred to herein as PAS-nomacopan and PAS-L-Nomacopan, have been shown to improve clinical scores and composite histological scores in an experimental autoimmune uveitis (EAU) model. These molecules also reduce the population of Th17 cells (and IL-17). The Th17 subset has been detected in human uveitis and mediates disease in EAU. When applied topically, nomacopan, L-nomacopan and long-acting nomacopan also had an effect on clinical scores in these mice, which was considered unexpected since this molecule was not thought to penetrate the cornea.
[0024] The inventors have also shown that induction with RBP3 (also known as IRBP) in a separate mouse model of EAU resulted in a significant increase in VEGF levels in retinal tissue. Intravitreal injection of nomacopan-type proteins resulted in a decrease in VEGF levels, as did intravitreal injection of anti-VEGF antibodies (Examples 4 and Fig. 7A ). Because nomacopan and its variants are not known to have any direct effect on VEGF, it is proposed that this is an indirect effect through at least inhibition of LTB4 activation of the above-mentioned M2 macrophages, which are believed to be the main source of VEGF in this model. It is also believed that the clearance of LTB4 from neutrophils by nomacopan-type proteins also has the effect of reducing the retinal to peripheral blood LTB4 concentration gradient, thereby reducing inflammatory cell trafficking of Th17 cells (as shown in Example 3) and macrophages.
[0025] Nomacopan is able to inhibit LTB4 and is therefore particularly advantageous in the prevention and treatment of proliferative retinal diseases, either alone or in combination with other treatments. In addition, it can inhibit the complement pathway (by inhibiting C5), which provides certain advantages, for example, in cases where the complement pathway is involved in disease pathology. Modified forms of nomacopan that inhibit LTB4 but not C5 may also be useful, and particularly in cases where inhibition of the complement pathway may not be desirable.
[0026] Nomacopan has been previously disclosed as a potential treatment for ocular surface conditions (e.g., atopic keratoconjunctivitis, by administering the protein to the ocular surface, see, e.g., WO2018193120), but it was not previously known that the molecule could penetrate the cornea and therefore could be administered topically to treat ocular conditions that are not ocular surface conditions, nor was it previously known that the molecule could be effective when administered directly into the eye. For example, even when administered directly into the eye, the therapeutic molecule may not be able to reach the location where it is required to act effectively due to the presence of various barriers, such as the internal limiting membrane and Bruch's membrane. Indeed, various previous complement inhibitor molecules have been previously tested for ocular conditions but have not been found to be effective (see, e.g.,
[26] ).
[0027] Therefore, prior to the present study, it was not known that nomacopan-type proteins could be used to treat proliferative retinal diseases by topical administration or by direct introduction into the eye. Furthermore, it was not known that nomacopan-type proteins could be used to reduce VEGF levels in retinal tissue. Summary of the invention
[0028] It has now been shown that nomacopan-type proteins reduce clinical scores in an experimental autoimmune uveitis mouse model when applied topically or by direct introduction into the eye. This suggests that the protein can be used to treat uveitis, and supports the use of the protein for the treatment of proliferative retinal diseases alone or in combination with other treatments. Nomacopan also has the ability to inhibit the complement pathway (by inhibiting C5) as well as LTB4, and is therefore particularly advantageous in the prevention and treatment of proliferative retinal diseases alone or in combination with other treatments in the presence of complement components as well. The dual functionality of the protein can be further manipulated so that a modified form thereof that binds LTB4 but not C5 (e.g. L-nomacopan) can be particularly advantageous in the prevention and treatment of proliferative retinal diseases in the absence of complement components and / or where inhibition of the complement system may be disadvantageous. Again, this can be alone or in combination with other treatments.
[0029] In Example 1, topical administration of nomacopan-type proteins reduced clinical scores in an experimental autoimmune uveitis model in a mouse model. In subsequent examples, intravitreal administration of nomacopan-type proteins reduced clinical scores in an experimental autoimmune uveitis model in a mouse model.
[0030] The inventors have thus demonstrated that administration of the tick protein Nomacopan (also known in the art and herein
[24] as EV576 and OmCI, and previously referred to as "Coversin") and variants thereof can be used to treat or prevent autoimmune uveitis and other proliferative retinal diseases.
[0031] Therefore, the present invention provides a method for treating or preventing proliferative retinal diseases, which comprises administering a therapeutically or preventively effective amount of an agent which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein.
[0032] The present invention also provides an agent for use in a method for treating or preventing a proliferative retinal disease, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in FIG. 2 (SEQ ID NO: 2) or a functional equivalent of the protein.
[0033] The present invention also provides a method for treating or preventing a proliferative retinal disease in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, wherein the agent is a nucleic acid molecule encoding a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein.
[0034] The present invention also provides an agent for use in a method for treating or preventing proliferative retinal diseases, which is a nucleic acid molecule encoding a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein.
[0035] The present invention also provides a method for treating or preventing a proliferative retinal disease in a subject, comprising administering to the subject (a) a therapeutically or prophylactically effective amount of an agent, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein, and (b) a second proliferative retinal disease treatment.
[0036] The present invention also provides (a) an agent which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein for use in a method of treating or preventing a proliferative retinal disease, and (b) a second proliferative retinal disease treatment.
[0037] The present invention also provides a method for treating or preventing a proliferative retinal disease in a subject, comprising administering to the subject (a) a therapeutically or prophylactically effective amount of an agent, which is a nucleic acid molecule encoding a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein, and (b) a second proliferative retinal disease treatment.
[0038] The present invention also provides (a) an agent which is a nucleic acid molecule encoding a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein, and (b) a second proliferative retinal disease for use in a method of treating or preventing a proliferative retinal disease.
[0039] The present invention also provides a method for reducing the amount of a second proliferative retinal disease treatment required to treat or prevent a proliferative retinal disease, or reducing the duration of treatment required to treat or prevent a proliferative retinal disease with a second proliferative retinal disease treatment, or increasing the amount of time between consecutive treatments with the second proliferative retinal disease treatment, the method comprising administering a therapeutically or prophylactically effective amount of an agent, the agent being a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein, or a nucleic acid molecule encoding the agent, and the second proliferative retinal disease treatment.
[0040] Example 4 demonstrates that nomacopan-type proteins are effective in reducing VEGF levels in a mouse model of EAU. Since nomacopan and its variants are not known to have any direct effect on VEGF, this is proposed to be an indirect effect through inhibition of the above-mentioned LTB4 activation of M2 macrophages, which are believed to be the major source of VEGF in this model.
[0041] Thus, the agents and methods of the invention can prevent or treat proliferative retinal diseases as described elsewhere herein by reducing, for example, VEGF levels in retinal tissue. For example, by reducing VEGF signaling in retinal tissue. The reduced effect in turn causes, for example, a reduction in angiogenesis and / or a reduction in vascular permeability.
[0042] The agents and methods of the invention may also prevent or treat proliferative retinal diseases as described elsewhere herein by reducing LTB4 activation of M2 macrophages. DETAILED DESCRIPTION
[0043] disease
[0044] Proliferative retinal diseases are retinal conditions that involve the formation of blood vessels on the retina. For example, blood vessels can be generated in response to a decrease in blood supply caused by retinal ischemia. This new angiogenesis generally occurs in response to the growth hormone vascular endothelial growth factor (VEGF), which stimulates the generation of new blood vessels on the optic disc or retinal surface. However, these new blood vessels are particularly weak, prone to leakage and can easily break, leading to bleeding and severe visual loss. Possible proliferative retinal diseases include autoimmune uveitis, infectious uveitis, wet age-related macular degeneration (choroidal neovascularization), dry age-related macular degeneration (map-like atrophy), diabetic retinopathy, diabetic macular edema, optic neuritis (e.g., glaucoma-related), retinal vein occlusion, and retinopathy of prematurity. Other proliferative retinal diseases include Stargardt's disease and polypoidal choroidal vasculopathy.
[0045] The inventors have tested nomacopan, L-nomacopan, PAS-nomacopan and PAS-L-nomacopan in experiments in an experimental autoimmune uveitis mouse model. Certain molecules were administered topically. Certain molecules were administered intravitreally. As stated in Examples 1 and 3, displaying nomacopan-type proteins can reduce clinical scores in this mouse model. The data presented below also show that these molecules can reduce the population of Th-17 cells and thereby reduce IL-17 levels. The inventors have also shown that in this mouse model, LTB4 receptors (BLT1) can be observed on cells infiltrating into the mouse retina. In addition, these nomacopan-type molecules can bind to LTB4 and inhibit its effects.
[0046] The ability of the tested molecules to reduce LTB4 signaling is consistent with the observation that upon retinal injury, M2 macrophages migrate and attach to damaged areas of the retina. These M2 macrophages then release VEGF in response to LTB4 stimulation, which stimulates the creation of new blood vessels
[35] . Therefore, without wishing to be bound by any theory, it is believed that administration of nomacopan-type proteins results in a decrease in VEGF levels, which reduces and / or prevents the creation of new blood vessels. This theory is consistent with Examples 4 and Fig. 7A The data in , which show that in a mouse model of EAU, administration of nomacopan-type proteins significantly reduces the levels of VEGF in retinal tissue.
[0047] Therefore, nomacopan-type proteins can be used to treat or prevent proliferative retinal diseases. Therefore, the present invention provides a method for preventing or treating a proliferative retinal disease in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, the agent being a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In addition, the present invention provides an agent, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein, for preventing or treating a proliferative retinal disease.
[0048] The presence of these diseases can be determined by routine diagnostic tests that are well understood in the art. The severity of certain symptoms can also be scored, which can be used to assess whether a certain treatment is effective.
[0049] Uveitis
[0050] Autoimmune uveitis is an inflammatory process of the uveal components (iris, ciliary body and choroid) due to autoimmune reactions to self-antigens, or caused by innate inflammatory reactions secondary to external stimuli. It can exist in different anatomical forms - anterior, intermediate, posterior or diffuse. Anterior uveitis is the most common form of the disease, which manifests as iritis affecting the iris or iridocyclitis affecting the ciliary body. Intermediate uveitis or vitritis involves the vitreous cavity and may involve the pars plan, and posterior uveitis is divided into three types: choroiditis, retinochoroiditis and chorioretinitis. Chorioretinitis is often associated with infectious diseases, such as toxoplasmosis. When diffuse involvement or uveitis affects many areas, it is described as panuveitis.
[0051] The type of uveitis can be classified using the International Uveitis Study Group (IUSG) classification, and the Standard Uveitis Nomenclature (SUN) group can be used to define guidelines for the onset, duration, and course of uveitis
[27] . Uveitis primarily affects people aged 20 to 50 years; although it can occur at any age and even affect children. Uveitis rates are also higher in patients aged 65 years or older.
[0052] As shown in Examples 1 and 3, nomacopan-type proteins have been shown to reduce clinical and histological scores in a mouse model of autoimmune uveitis (EAU).
[0053] In addition, the CD4+ T cell subset Th17 cells produce interleukin (IL)-17, a proinflammatory cytokine that has been shown to be involved in several forms of infectious and non-infectious uveitis. IL-17 induces the production of other inflammatory cytokines, such as IL-6, granulocyte colony stimulating factor (CSF), granulocyte-macrophage-CSF, IL-1, TGF-β, and tumor necrosis factor (TNF)-α
[28] . The examples also demonstrate that nomacopan-type proteins can reduce the percentage of CD4+ cells expressing IL-17. Without wishing to be bound by any particular theory, these molecules can reduce the level of Th17 cells that produce IL-17, which results in reduced inflammation in the uvea, thereby reducing the progression of uveitis. Therefore, nomacopan-type proteins may be particularly useful for treating or preventing autoimmune uveitis or infectious uveitis.
[0054] VEGF plays an important role in the inflammatory process by promoting angiogenesis and increasing vascular permeability. VEGF expression is associated with many major cytokines in the inflammatory cascade, including NFκB. The importance of VEGF in the development of retinal neovascularization is well recognized
[29] . Nomacopan-type proteins can bind to LTB4 and inhibit its action, which is proposed to reduce the level of VEGF expression in M2 macrophages. This is shown in Examples 4 and Fig. 7A The results were presented in an EAU mouse model in , which showed that nomacopan-type proteins reduce VEGF levels in retinal tissue. The resulting reduction in VEGF levels prevents the generation of new blood vessels. Therefore, nomacopan-type proteins can be used to treat or prevent autoimmune uveitis or infectious uveitis.
[0055] In a preferred embodiment, the present invention provides a method for preventing or treating autoimmune uveitis in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, the agent being a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In addition, the present invention provides an agent for preventing or treating autoimmune uveitis, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein.
[0056] In certain embodiments, the present invention provides a method for preventing or treating infectious uveitis in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, the agent being a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In addition, the present invention provides an agent for preventing or treating infectious uveitis, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein.
[0057] In certain embodiments, the autoimmune uveitis may be anterior uveitis, intermediate uveitis, posterior uveitis, or diffuse uveitis. In a preferred embodiment, the present invention provides a method for preventing or treating anterior uveitis in a subject. Also provided is a composition of the present invention for preventing or treating anterior uveitis in a subject.
[0058] Subjects at risk of developing autoimmune uveitis may benefit from administration of the agents mentioned herein to prevent autoimmune uveitis. Risk factors for uveitis include smoking. Subjects who are smokers or former smokers are preferred in treating or preventing autoimmune uveitis. In some embodiments, a subject may have one or more of these risk factors but may not exhibit any clinical symptoms.
[0059] The subject to be treated can be between 20 and 50 years old. In some embodiments, the subject is older than 65 years old. In some embodiments, the subject is 18 years old or older. In other embodiments, the subject is younger than 18 years old.
[0060] Age-related macular degeneration
[0061] Age-related macular degeneration (AMD) is a degenerative retinal eye disease that causes a progressive, irreversible, and severe loss of central vision. The disease damages the macula, the area of highest visual acuity, and is one of the leading causes of blindness in Americans aged 60 or older.
[0062] There are two types of AMD, wet and dry AMD. Wet AMD (also known as neovascular AMD) is associated with rapid deterioration of vision and severe impairment. Visual function is severely impaired in wet AMD, and eventually inflammation and scarring cause permanent loss of visual function in the affected retina. Wet AMD has two subtypes, 'classic' and 'occult'. In the classic subtype, the new blood vessels can be clearly seen by an ophthalmologist using angiography, while in the occult subtype, the leaking blood vessels are hidden. Patients may present with a combination of occult and classic CNVs
[30] .
[0063] Wet AMD is characterized, inter alia, by abnormal new blood vessel formation in and beneath the optic nerve retina in response to various stimuli. This abnormal blood vessel growth results in the formation of leaky blood vessels that often bleed. Abnormal blood vessel growth is activated by VEGF. Nomacopan-type proteins can bind to and inhibit LTB4, which is known to activate VEGF. Therefore, nomacopan-type proteins can be particularly effective in treating wet AMD.
[0064] Dry AMD (also known as atrophic AMD) accounts for about 80% of cases and usually develops slowly, usually affecting both eyes at the same time. It usually causes only slight visual loss. Dry AMD is characterized by fatty deposits behind the retina, which thins and dries out the macula.
[0065] AMD can be self-assessed using the STARS questionnaire
[31] . AMD can be classified based on fundus lesions assessed within 2 optic disc diameters of the fovea in people over 55 years of age. Subjects without visible drusen or pigmentary abnormalities should be considered to have no signs of AMD. People with small drusen (<63 μm), also called drupelets, should be considered to have normal aging changes without an increased risk of clinically relevant development of late AMD. People with medium drusen (≥63-<125 μm) but no pigmentary abnormalities considered to be associated with AMD should be considered to have early AMD. People with large drusen or pigmentary abnormalities associated with at least medium drusen should be considered to have intermediate AMD. People with lesions associated with neovascular AMD or geographic atrophy should be considered to have late AMD
[32] .
[0066] Increased local and systemic complement activation has been observed in AMD. Polymorphisms in multiple complement genes increase the risk of AMD
[33] . Nomacopan is known to inhibit the complement activating factor C5. Therefore, nomacopan-type proteins that bind to C5 may be effective in treating AMD by inhibiting activation of the complement pathway.
[0067] The LTB4 receptor has been shown to promote laser-induced choroidal neovascularization in a mouse model for wet AMD, and expression of VEGF mRNA has been spatially and temporally associated with neovascularization in several animal models of retinal ischemia [34, 35]. As previously discussed, nomacopan-type proteins can inhibit LTB4. This can lead to a decrease in VEGF levels, which prevents the generation of new blood vessels. Therefore, nomacopan-type proteins can be used to treat or prevent AMD.
[0068] Therefore, the present invention provides a method for preventing or treating wet age-related macular degeneration in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, the agent being a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In other embodiments, the present invention provides an agent for preventing or treating wet age-related macular degeneration, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. Wet age-related macular degeneration may be latent, classic, or a combination thereof.
[0069] In addition, the present invention provides a method for preventing or treating dry age-related macular degeneration in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, the agent being a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In other embodiments, the present invention provides an agent for preventing or treating dry age-related macular degeneration, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein.
[0070] In a preferred embodiment, the subject to be treated is 60 years of age or older.
[0071] Subjects with a risk of suffering from AMD may benefit from administering the agents mentioned herein to prevent AMD. Risk factors for AMD include smoking, sunlight, artificial fats (such as partially hydrogenated vegetable oils), processed, packaged foods, and a diet high in fresh vegetables, uncontrolled high blood pressure and high cholesterol, diabetes, advanced age (patients over 60 years of age face a greater risk than younger patients), and obesity.
[0072] For the treatment or prevention of AMD, subjects having one or more of these risk factors are preferred.In some embodiments, a subject may have one or more of these risk factors but may not exhibit clinical symptoms.
[0073] Diabetic retinopathy
[0074] Diabetes mellitus significantly affects the microvasculature in nearly every tissue. Diabetic retinopathy is characterized by microaneurysms, hard exudates, hemorrhages, and venous abnormalities. Hyperglycemia induces microvascular retinal changes that produce blurred vision, dark spots or flashes, and sudden blindness
[36] .
[0075] There are three different types of diabetic retinopathy - background retinopathy, diabetic maculopathy and proliferative retinopathy. Background retinopathy, also known as simple retinopathy, involves tiny swellings in the walls of blood vessels. They are called blebs, which appear as small spots on the retina and are often accompanied by yellow patches of exudate (blood protein). Diabetic maculopathy is when the macula is damaged in some way. One of the causes of macular damage is from diabetic macular edema, whereby blood vessels near the macula leak fluid or protein onto the macula. Proliferative retinopathy is an advanced stage of diabetic retinopathy, in which the retina becomes blocked, causing abnormal blood vessels to grow. These can then seep into the eye, causing the retina to detach and severely damage vision. If untreated, this can cause blindness
[36] .
[0076] VEGF is an important factor in the development of diabetic retinopathy. Nomacopan-type proteins can bind to and inhibit LTB4, which can cause a decrease in VEGF levels. Therefore, nomacopan-type proteins can be used to treat or prevent diabetic retinopathy.
[0077] Therefore, the present invention provides a method for preventing or treating diabetic retinopathy in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, the agent being a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In addition, the present invention provides an agent for preventing or treating diabetic retinopathy, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. Diabetic retinopathy may be background retinopathy, diabetic maculopathy, or proliferative retinopathy.
[0078] The subject in need of treatment may have type 1 or type 2 diabetes. The longer the subject has had diabetes, and if blood sugar levels are not adequately controlled, the higher the probability of developing diabetic retinopathy. In some embodiments, the subject has had diabetes for at least 5, 10, 20, 30 or 40 years.
[0079] Other risk factors include high blood pressure, high cholesterol, pregnancy, tobacco use, and being African American, Hispanic, or Native American.
[0080] Subjects at risk of developing diabetic retinopathy may benefit from administration of the agents mentioned herein to prevent diabetic retinopathy. Subjects with one or more of these risk factors are preferred for the treatment or prevention of diabetic retinopathy. In some embodiments, a subject may have one or more of these risk factors but may not show clinical symptoms.
[0081] Optic neuropathy
[0082] Optic neuropathy develops after damage to the optic nerve. The classic clinical signs of optic neuropathy are visual field loss, color vision impairment, and abnormal papillary reactions. The main symptom is visual loss, where colors appear subtly faded in the affected eye. In many cases, only one eye is affected, and the patient may not be aware of the color vision loss until the doctor asks them to cover the healthy eye.
[0083] Rapid onset of optic neuropathy is characteristic of optic neuritis, ischemic optic neuropathy, inflammatory (non-demyelinating), and traumatic optic neuropathies. A gradual progression of symptoms is observed in compressive toxic / nutritional optic neuropathy.
[0084] There are several types of optic neuropathy, including:
[0085] (a) Ischemic optic neuropathies, in which blood flow to the optic nerve is inadequate. These include anterior ischemic optic neuropathy, which affects the optic nerve head and causes swelling of the optic disc, and posterior ischemic optic neuropathy, which does not involve swelling of the optic disc;
[0086] (b) Optic neuritis, which is an inflammation of the optic nerve and is associated with swelling and damage to the myelin sheath covering the optic nerve. Optic neuritis can be classified as simple isolated optic neuritis, relapsing isolated optic neuritis, chronic relapsing inflammatory optic neuropathy, neuromyelitis optica spectrum disorder, multiple sclerosis-associated optic neuritis, and classified forms of optic neuritis. Optic neuritis can also be associated with glaucoma;
[0087] (c) Compressive optic neuropathy, which is caused by tumors, infections, and inflammatory processes that cause lesions within the orbit and, less commonly, the optic canal. The lesions compress the optic nerve causing swelling of the optic disc and progressive visual loss. Involved orbital conditions include optic nerve gliomas, meningiomas, hemangiomas, lymphangiomas, dermoid cysts, carcinomas, lymphomas, multiple myeloma, inflamed orbital pseudotumors, and thyroid eye disease;
[0088] (d) Infiltrative optic neuropathy, in which the optic nerve is infiltrated by a variety of processes, including tumors, inflammation, and infection. The most common inflammatory condition that infiltrates the optic nerve is sarcoidosis. Opportunistic fungi, viruses, and bacteria can also infiltrate the optic nerve. If infiltration occurs in the proximal portion of the nerve, the optic nerve may be elevated. The appearance of the nerve on examination depends on the portion of the nerve affected;
[0089] (e) Traumatic optic neuropathy, in which the optic nerve is damaged when exposed to direct or indirect injury. Falls are also a common cause, and optic neuropathy most often occurs when there is loss of consciousness associated with multisystem trauma and severe brain injury;
[0090] (f) Mitochondrial optic neuropathy. Mitochondria play an important role in maintaining the life cycle of retinal ganglion cells due to their high energy dependence. Gene mutations in mitochondrial DNA, vitamin deficiency, alcohol and tobacco abuse, and the use of certain drugs can cause disturbances in the efficient transport of mitochondria, which can cause primary or secondary optic neuropathy;
[0091] (g) Nutritional optic neuropathy, which is caused by a lack of nutrients in the patient's diet. Nutritional deficiencies affect the whole body, so pain or loss of sensation in the arms and legs (peripheral neuropathy) is often found in patients with nutritional optic neuropathy;
[0092] (h) Toxic optic neuropathy. The most common cause is methanol poisoning;
[0093] (i) Hereditary optic neuropathies, which usually present as symmetrical bilateral central vision loss. Possible hereditary optic neuropathies include: Leber's hereditary optic neuropathy, dominant optic atrophy, Behr's syndrome, and Berk-Tabatznik syndrome.
[0094] Therefore, the present invention provides a method for preventing or treating optic neuropathy conditions in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In addition, the present invention provides an agent for preventing or treating optic neuropathy conditions, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein.
[0095] In some embodiments, the optic neuropathy condition includes any condition in which the optic nerve is damaged. The optic neuropathy condition can be selected from: optic neuritis, ischemic optic neuropathy, compressive optic neuropathy, infiltrative optic neuropathy, traumatic optic neuropathy, mitochondrial optic neuropathy, nutritional optic neuropathy, toxic optic neuropathy, and hereditary optic neuropathy. In a preferred embodiment, the optic neuropathy condition is glaucoma-related optic neuritis.
[0096] Retinal vein occlusion
[0097] Retinal vein occlusion is a vascular disorder of the retina. It is the second most common cause of blindness after diabetic retinopathy and occurs primarily in patients over 60 years of age. There are three types of retinal vein occlusion. The first is a branch retinal vein occlusion caused by a blockage in one of the four retinal veins. The second is a central retinal vein occlusion caused by a blockage of the main retinal vein, and the third is a branch retinal vein occlusion, in which the blockage occurs at the distal branches of the retinal veins. Central retinal vein occlusion generally results in more severe visual loss. Depending on the amount of retinal capillary ischemia, retinal vein occlusion can be further subdivided into non-ischemic and ischemic types
[37] .
[0098] Retinal vein occlusion can be diagnosed using optical coherence tomography. This involves taking high-definition images of the retina using a scanning ophthalmoscope with a 5-micrometer resolution. These images can determine the presence of swelling and edema by measuring the thickness of the retina. Ophthalmoscopy and fluorescein angiography can also be used to diagnose retinal vein occlusion by examining the retina and retinal blood vessels, respectively.
[0099] The two main complications of retinal vein occlusion are macular edema and retinal ischemia, which causes neovascularization of the iris and retina. After the blockage occurs in the renal vein, pressure builds up in the capillaries, causing bleeding and leakage of fluid and blood. Neovascularization, the growth of new abnormal blood vessels, then occurs, which can lead to neovascular glaucoma, vitreous hemorrhage, and in advanced or severe cases, retinal detachment
[37] . VEGF plays a major role in the pathogenesis of retinal vein occlusion because, in the presence of ischemia, VEGF is secreted, which causes further vascular leakage and retinal edema
[38] .
[0100] Nomacopan-type proteins can bind to and inhibit LTB4, which can cause a decrease in VEGF levels. Therefore, nomacopan-type proteins can be used to treat or prevent diabetic retinopathy. Therefore, the present invention provides a method for preventing or treating retinal vein occlusion in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, the agent being a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In addition, the present invention provides an agent for preventing or treating retinal vein occlusion, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. Retinal vein occlusion can be a branch retinal vein occlusion, a central retinal vein occlusion, or a semi-central retinal vein occlusion.
[0101] In some embodiments, the subject is 60 years of age or older, 65 years of age or older, 70 years of age or older, or 80 years of age or older. In preferred embodiments, the subject is 65 years of age or older.
[0102] Retinopathy of prematurity
[0103] Retinopathy of prematurity (ROP) is one of the leading causes of blindness in children and is characterized by retinal neovascularization that can eventually lead to tractional retinal detachment. ROP affects approximately 20% of premature infants. It occurs primarily in infants born before the 32nd week of gestation or in infants weighing less than 1500 g at birth.
[0104] ROP has no external symptoms, so all premature infants born before the 32nd week of gestation or weighing less than 1.5 kg are screened weekly or biweekly by ophthalmologists. The extent and severity of ROP are traditionally described according to the International Classification of ROP, defined by location (zone; I to III), severity (stage; 1 to 5), degree (clock time; 1 to 12), and vascular dilation and tortuosity (plus disease)
[39] .
[0105] Blood vessels normally develop between the 16th and 36th weeks of gestation, and VEGF plays a key role in angiogenesis in the fetus. During normal development, VEGF is released in response to the higher oxygen demand of retinal tissue, which leads to the development of blood vessels. However, in premature infants, VEGF levels are elevated, which leads to abnormal blood vessel proliferation
[40] .
[0106] Therefore, the present invention provides a method for preventing or treating retinopathy of prematurity in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In addition, the present invention provides an agent for preventing or treating retinopathy of prematurity, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein.
[0107] In some embodiments, the subject is a premature infant born before 27 weeks of gestational age, born between 27 and 32 weeks of gestational age, or born after >32 weeks of gestational age but with a birth weight <1501 grams.
[0108] Pre-Proliferative retinal disease
[0109] The subject may have, be suspected of having, or be at risk of having a proliferative retinal disease. For example, the subject may have proliferative retinopathy. Proliferative retinopathy indicates the occurrence of chronic retinal ischemia due to capillary blockage. Clinical signs of proliferative retinopathy include multiple cotton wool spots, venous beading and / or looping, multiple deep circular and macular hemorrhages, and intraretinal microvascular abnormalities.
[0110] As mentioned previously, proliferative retinal diseases are characterized by neovascularization, which is activated by VEGF. VEGF promotes vascular permeability and angiogenesis, which can cause abnormal production of blood vessels in proliferative retinal diseases. Nomacopan-type proteins can bind to and inhibit LTB4, which can reduce VEGF levels. This is shown, for example, in Example 4.
[0111] Therefore, the present invention provides a method for preventing or treating a proproliferative retinal disease in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In addition, the present invention provides an agent for preventing or treating a proproliferative retinal disease, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein.
[0112] Stargardt's disease
[0113] Stargardt's disease is an inherited macular dystrophy caused by mutations in the ABCA4 gene, which encodes a retinal transporter protein. It is the most common form of childhood macular degeneration, with an estimated incidence of approximately 10 to 12.5 cases per 100,000 individuals in the United States. Patients with Stargardt's disease develop severe visual loss within the first decade or two of their life, which progresses to irreversible reduction in visual acuity in almost all cases
[41] .
[0114] The pathology may include choroidal neovascularization, in which case intravitreal anti-VEGF injections are performed
[42] . The present inventors have shown that nomacopan-type proteins can reduce VEGF levels in proliferative retinal diseases.
[0115] Therefore, the present invention provides a method for preventing or treating Stargardt's disease in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In addition, the present invention provides an agent for preventing or treating Stargardt's disease, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein.
[0116] Polypoidal choroidal vasculopathy
[0117] Polypoidal choroidal vasculopathy (PCV) is a disease of the choroidal vasculature. It occurs in men and women of many ethnicities and is characterized by serosanguinary sloughing of the pigment epithelium and exudative changes that often lead to subretinal fibrosis. Evidence supports that symptomatic patients with PCV can completely regress without severe visual loss under photodynamic therapy and anti-VEGF treatment
[43] . The present inventors have shown that nomacopan-type proteins can reduce VEGF levels in proliferative retinal diseases.
[0118] Therefore, the present invention provides a method for preventing or treating polypoidal choroidal vasculopathy in a subject, comprising administering a therapeutically or prophylactically effective amount of an agent, the agent being a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In addition, the present invention provides an agent for preventing or treating polypoidal choroidal vasculopathy disease, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein. In some embodiments, the agent is administered in combination with photodynamic therapy.
[0119] Application results
[0120] The subject may have a reduced incidence of symptoms, relief of symptoms, inhibition or delay of symptom occurrence or recurrence, or a combination thereof, as a result of treatment. Preferably, treatment results in a reduction in symptoms of typical disease conditions. For example, visual acuity is used as an endpoint in many clinical studies of treatments for proliferative retinal diseases. Treatment according to the invention may therefore result in an improvement in visual acuity.
[0121] As a result of treatment, the subject may demonstrate an improvement in his clinical score, for example using one of the methods mentioned above in relation to one of the specific diseases.
[0122] In addition, due to treatment, the subject can show reduced vascularization or reduced vascular proliferation (e.g., in the eye). Other results may include an increase in visual acuity, a reduction in visual loss, an increase in visual recovery, a reduction in central retinal thickness and / or an improvement in diabetic retinopathy severity score. In addition, treatment may reduce vitreous hemorrhage, iris or anterior vascularization, neovascular glaucoma and / or retinal detachment. The reduction observed after administration of the active agent can be measured relative to healthy individuals, individuals with more severe forms of related proliferative retinal diseases, or observed in patients before treatment with the active agent.
[0123] Treatment can result in reduced retinal inflammation, reduced numbers of Th17 cells, and reduced numbers of CD4+ cells expressing RORgt / Tbet (eg, in uveitis).
[0124] Treatment may also result in a reduction in the amount or duration or frequency of treatment required for the secondary disease.
[0125] Therefore, in another embodiment of the present invention, there is provided a method of improving visual acuity, improving clinical scores, reducing angiogenesis or vascular proliferation (e.g., in the eye), reducing visual loss, increasing visual recovery, reducing central retinal thickness and / or improving diabetic retinopathy severity score, reducing vitreous hemorrhage, reducing iris or corneal neovascularization, reducing neovascular glaucoma and / or retinal detachment, reducing inflammation, reducing the number of Th17 cells and / or reducing the number of CD4+ cells expressing RORgt / Tbet (e.g., in uveitis) in a subject suffering from a retinal proliferative disease, the method comprising administering a therapeutically or prophylactically effective amount of an agent, the agent being a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein, or a nucleic acid molecule encoding the agent. This may be alone or in conjunction with a second retinal proliferative disease treatment.
[0126] The present invention also provides an agent, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein, a nucleic acid molecule encoding the agent, which is used in a method of improving visual acuity, improving clinical scores, reducing angiogenesis or vascular proliferation (e.g., in the eye), reducing visual loss, increasing visual recovery, reducing central retinal thickness and / or improving diabetic retinopathy severity scores, reducing vitreous hemorrhage, reducing iris or corneal neovascularization, reducing neovascular glaucoma and / or retinal detachment, reducing inflammation, reducing the number of Th17 cells and / or reducing the number of CD4+ cells expressing RORgt / Tbet (e.g., in uveitis) in a subject with a retinal proliferative disease.
[0127] In another embodiment of the present invention, a method for treating or preventing a proliferative retinal disease in a subject is provided, the method comprising administering a therapeutically or prophylactically effective amount of an agent, the agent being a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein, or a nucleic acid molecule encoding the agent, wherein the agent causes, for example, a decrease in VEGF levels in retinal tissue, and / or the agent causes, for example, a decrease in VEGF signaling in retinal tissue.
[0128] The present invention also provides an agent for use in a method for treating or preventing a proliferative retinal disease in a subject, which is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of the protein, or a nucleic acid molecule encoding the agent, wherein the agent causes, for example, a decrease in VEGF levels in retinal tissue, and / or the agent causes, for example, a decrease in VEGF signaling in retinal tissue.
[0129] The reagent of the present invention can be used in combination with other retinal proliferative disease treatments as discussed above. The combination of the reagent of the present invention and another (herein referred to as "second") retinal proliferative disease treatment can reduce the amount of the second reagent compared to the amount used in the absence of the reagent treatment of the present invention, or reduce the duration of the treatment of the second reagent compared to the duration of the treatment used in the absence of the reagent treatment of the present invention, or reduce the frequency of the second reagent. In view of the side effects of certain known treatments, this is advantageous. Therefore, a method for reducing the amount of the second treatment, reducing the frequency of application of the second treatment, or reducing the duration of the second treatment is also provided, the method comprising administering a therapeutic or preventive effective amount of the reagent, the reagent being a protein comprising amino acids 19 to 168 of the amino acid sequence (SEQ ID NO:2) in Figure 2 or a functional equivalent of the protein, and optionally further comprising administering the second treatment.
[0130] When a second retinal proliferative disease treatment is used, it is preferably selected from an anti-inflammatory drug, such as a steroid, such as a corticosteroid; an IMT drug, such as methotrexate, azathioprine and mycophenolate mofetil; a BRM drug (such as an anti-TNFα agent, such as an antibody or fragment thereof that binds TNFα, such as infliximab or adalimumab); an anti-VEGF treatment, such as an anti-TNFα antibody or fragment thereof (such as bevacizumab, ranibizumab (Lesuqing), an anti-VEGF aptamer (such as pegaptanib (Magujin)), or another VEGF antagonist, such as aflibercept (Elia, a recombinant fusion protein consisting of the vascular endothelial growth factor (VEGF) binding portion from the extracellular domain of human VEGF receptors 1 and 2 fused to the Fc portion of a human IgG1 immunoglobulin).
[0131] When a nomacopan-type protein and a second agent are used, they may be administered together or separately. The nomacopan-type protein may be administered first and the second retinal proliferative disease treatment may be administered second, or vice versa.
[0132] Thus, for example, in the methods as described above, when an agent of the invention is used in combination with one or more other retinal proliferative disease treatments, this can be described as (i) an agent comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO:2) or a functional equivalent of said protein for use in a method of treating or preventing a retinal proliferative disease together with a second retinal proliferative disease treatment, or (ii) a second retinal proliferative disease treatment for use in a method of treating or preventing a retinal proliferative disease together with an agent comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO:2) or a functional equivalent of said protein, or (iii) an agent comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO:2) or a functional equivalent of said protein for use in a method of treating or preventing a retinal proliferative disease and a second retinal proliferative disease treatment. In each of (i) to (iii), the method comprises administering an agent that is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO:2) or a functional equivalent of the protein and administering a second retinal proliferative disease treatment.
[0133] In some embodiments, an agent that is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO:2) or a functional equivalent of the protein is administered topically, and the second retinal proliferative disease treatment is administered topically or directly into the eye, such as intravitreally or suprachoroidally, preferably directly into the eye, such as intravitreally or suprachoroidally.
[0134] In some embodiments, an agent that is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO:2), or a functional equivalent of said protein, is administered directly into the eye, e.g., intravitreally or suprachoroidally, and a second retinal proliferative disease treatment is administered topically or directly into the eye, e.g., intravitreally or suprachoroidally.
[0135] In some embodiments, the second retinal proliferative disease treating agent is also a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or a functional equivalent of said protein.
[0136] Where treatment results in a reduction in the amount or duration of a second retinal proliferative disease treatment, the reduction may be up to or at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% compared to the amount of the second treatment used in the absence of an agent of the invention.
[0137] Where the treatment results in a decrease in the frequency of treatment of the second retinal proliferative disease treatment, this may result in an increase in the time between administrations of the second retinal proliferative disease treatment by up to about 1, 2, 3, 4, 5, 6, 7 or 8 weeks.
[0138] Subjects
[0139] Preferred subjects, agents, dosages, etc. are as disclosed herein.
[0140] Any reduction or increase mentioned is a reduction or increase in a disease parameter of the subject compared to the absence of treatment. Preferably, the parameter can be quantified, and in this case, the increase or reduction is preferably statistically significant. For example, the increase or reduction can be at least 3, 5, 10, 15, 20, 30, 40, 50% or more compared to the parameter in the absence of treatment (e.g., before the start of the treatment).
[0141] In the practice of the present invention, the subject to which the agent is administered is preferably a mammal, preferably a human. The subject to which the agent is administered is at risk of or has a retinal proliferative disease.
[0142] The methods of the present invention may further comprise one or more of the following additional steps: (i) determining whether the subject is at risk for or has a retinal proliferative disease, (ii) determining the severity of the retinal proliferative disease, which may be performed before and / or after administering the agent of the present invention.
[0143] Reagents used in the present invention
[0144] According to one embodiment of the invention, the agent is nomacopan itself or a functional equivalent thereof. In the following, the term "nomacopan-type protein" is used as a shorthand for "a protein comprising amino acids 19 to 168 of the amino acid sequence shown in Figure 2 (SEQ ID NO: 2) or a functional equivalent thereof".
[0145] Nomacopan is isolated from the salivary glands of the Ornithodoros tick. Nomacopan is a peripheral member of the lipocalin family and is the first lipocalin family member to be shown to inhibit complement activation. Nomacopan inhibits the classical, alternative, and lectin complement pathways by binding to C5 and preventing its cleavage by the C5 convertase to C5a and C5b, thus inhibiting the generation of C5a, which is an active (e.g., proinflammatory) peptide, and the formation of MAC. Nomacopan has been shown to bind to C5 and prevent its cleavage by the C5 convertase at an IC50 of approximately 0.02 mg / ml in rat, mouse, and human serum.
[0146] Thus, a nomacopan-type protein may comprise or consist of amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2) or amino acids 1 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2). The first 18 amino acids of the protein sequence given in Figure 2 form a signal sequence, which is not essential for C5 binding or for LTB4 binding activity and can therefore optionally be omitted, for example for the sake of recombinant protein production efficiency.
[0147] C5 binding properties of nomacopan
[0148] It has been demonstrated that nomacopan protein binds to C5 with a Kd of 1 nM using surface plasmon resonance (SPR) assay
[44] . Nomacopan-type peptides (e.g., functional equivalents of nomacopan protein) preferably retain the ability to bind to C5, preferably having a Kd of less than 360 nM, more preferably less than 300 nM, most preferably less than 250 nM, preferably less than 200 nM, more preferably less than 150 nM, most preferably less than 100 nM, even more preferably less than 50, 40, 30, 20 or 10 nM, and advantageously less than 5 nM, wherein the Kd is preferably determined using surface plasmon resonance according to the method described in
[44] .
[0149] Nomacopan inhibits the classical complement pathway, the alternative complement pathway, and the lectin complement pathway. Preferably, nomacopan-type proteins bind to C5 in a manner that stabilizes the global conformation of C5 but does not directly block the C5 cleavage site targeted by the C5 convertases of the three activation pathways. The binding of nomacopan to C5 stabilizes the global conformation of C5 but does not block the convertase cleavage site. Functional equivalents of nomacopan also preferably share these properties.
[0150] C5 is cleaved by C5 convertase (Figure 1). The products of this cleavage include the anaphylatoxin C5a and the lytic complex C5b, which promotes the formation of a complex of C5b, C6, C7, C8, and C9, also known as the membrane attack complex (MAC). C5a is a highly proinflammatory peptide that is involved in many pathological inflammatory processes, including neutrophil and eosinophil chemotaxis, neutrophil activation, increased capillary permeability, and inhibition of neutrophil apoptosis
[45] .
[0151] Monoclonal antibodies and small molecules that bind to and inhibit C5 have been developed to treat various diseases
[46] , particularly PNH, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, and transplant rejection. However, some of these monoclonal antibodies do not bind to certain C5 proteins from subjects with C5 polymorphisms and are therefore ineffective in these subjects
[47] . Preferably, the nomacopan-type protein binds not only wild-type C5 but also C5 from subjects with a C5 polymorphism that renders treatment with eculizumab ineffective, or reduces the efficacy of eculizumab treatment, and inhibits the cleavage of both C5s). The term "C5 polymorphism" includes any form of C5 that has been altered compared to wild-type C5 by insertion, deletion, amino acid substitution, frameshift, truncation, any of which may be single or multiple, or a combination of one or more of these changes. In human subjects, wild-type C5 is considered to be the C5 protein having accession number NP_001726.2; GI version: 38016947. Examples of C5 polymorphisms include those at amino acid position 885, such as Arg885Cys (encoded by c.2653C>T), p.Arg885His (encoded by c.2654G>A), and Arg885Ser, which reduce the effectiveness of the mAb eculizumab
[47] .
[0152] The ability of an agent to bind C5, including C5 from a subject having a C5 polymorphism, e.g., a C5 polymorphism that renders treatment by eculizumab ineffective or reduces the efficacy of treatment with eculizumab, can be determined by standard in vitro assays known in the art, e.g., by surface plasmon resonance or Western blotting after incubation of the protein with labeled C5 on a gel. Preferably, the nomacopan-type protein binds to wild-type C5 and / or C5 from a subject having a C5 polymorphism, e.g., a C5 polymorphism that renders treatment by eculizumab ineffective or reduces the efficacy of treatment with eculizumab, with a Kd of less than 360 nM, more preferably less than 300 nM, most preferably less than 250 nM, preferably less than 200 nM, more preferably less than 150 nM, most preferably less than 100 nM, even more preferably less than 50, 40, 30, 20 or 10 nM, and advantageously less than 5 nM, wherein the Kd is preferably determined using surface plasmon resonance according to the method described in
[44] .
[0153] They may exhibit higher, lower, or the same affinity for wild-type C5 and C5 from subjects having a C5 polymorphism, e.g., a C5 polymorphism that renders treatment by eculizumab ineffective or reduces the efficacy of treatment with eculizumab.
[0154] The ability of a nomacopan-type protein to inhibit complement activation can also be determined by measuring the ability of an agent to inhibit complement activation in serum. For example, complement activity in serum can be measured by any means known in the art or described herein.
[0155] LTB4 binding properties of nomacopan
[0156] Nomacopan-type proteins may also be defined as having the function of inhibiting the activity of eicosanoids. Nomacopan has also been shown to bind to LTB4. Functional equivalents of nomacopan proteins may also retain the ability to bind to LTB4 with similar affinity as nomacopan proteins.
[0157] The ability of nomacopan-type proteins to bind LTB4 can be determined by standard in vitro assays known in the art, such as competitive ELISA by competition between nomacopan and anti-LTB4 antibodies for binding to labeled LTB4, by isothermal titration calorimetry, or by fluorescence titration. Data obtained using fluorescence titrations show that nomacopan binds to LTB4 with a Kd of 200 to 300 pM. For example, binding activity to LTB4 (Caymen Chemicals, Ann Arbor, MI, USA) in phosphate-buffered saline (PBS) can be quantified in a spectrofluorometer, such as an LS 50 B spectrofluorometer (Perkin-Elmer, Norwalk, CT, USA). This can be done as follows:
[0158] A purified 100 nM solution of nomacopan in 2 mL PBS was applied to a quartz cuvette (10 mm path length; Hellma, Mühlheim, Germany) equipped with a magnetic stirrer. The temperature was adjusted to 20 °C and after reaching equilibrium, protein Tyr / Trp fluorescence was excited at 280 nm (slit width: 15 nm). Fluorescence emission was measured at 340 nm (slit width: 16 nm), corresponding to the emission maximum. A ligand solution of 30 μM LTB4 in PBS was added stepwise up to a maximum volume of 20 μL (1% of the total sample volume) and steady-state fluorescence was measured after 30 s incubation. To calculate KD values, data were normalized to 100% of the initial fluorescence intensity, inner filter effects were corrected using titration of 3 μM N-acetyl-tryptophanamide solution and data were plotted against the corresponding ligand concentration. Subsequently, nonlinear least squares regression based on the mass action law of bimolecular complex formation was used to fit the data using Origin software version 8.5 (OriginLab, Northampton, MA, USA) using published formulas (Breustedt et al., 2006)
[48] .
[0159] Nomacopan can bind to LTB4 with a Kd of less than 1 nM, more preferably less than 0.9 nM, most preferably less than 0.8 nM, preferably less than 0.7 nM, more preferably less than 0.6 nM, most preferably less than 0.5 nM, even more preferably less than 0.4 nM and advantageously less than 0.3 nM, wherein the Kd is determined using a fluorescence titration, preferably according to the method described above. Nomacopan-type proteins preferably share these properties.
[0160] Molecules that bind to C5 and LTB4
[0161] According to one embodiment of the present invention, the nomacopan-type protein can bind to C5 and LTB4 (e.g., binds to wild-type C5 and C5 from a subject having a C5 polymorphism that is ineffective with, or has reduced efficacy of, eculizumab treatment, and binds to LTB4).
[0162] Nomacopan-type proteins can therefore be used to prevent complement C5 from being cleaved into complement C5a and complement C5b by the C5 convertase, and also to inhibit LTB4 activity. It can be advantageous to use an agent that binds to both C5 and LTB4. Both the C5 and eicosanoid pathways may contribute to the pathology observed in proliferative retinal diseases. Therefore, by using a single agent that inhibits multiple pathways involved in proliferative retinal diseases, an enhanced effect can be achieved compared to using an agent that inhibits only a single pathway. There are additional practical advantages associated with administering a single molecule.
[0163] Molecules that bind LTB4 but not C5 or exhibit reduced binding to C5
[0164] Nomacopan-type proteins that do not bind to C5 or exhibit reduced binding to C5 but do retain LTB-4 binding activity are disclosed, for example, in WO2018 / 193121, the entire contents of which are incorporated herein by reference. The nomacopan-type proteins having reduced or no C5 binding activity but retaining LTB-4 binding ability can be used in all aspects of the present invention.
[0165] The nomacopan-type protein having reduced or no C5 binding activity but retaining LTB-4 binding ability may comprise or consist of the following sequence:
[0166] SEQ ID NO:22 (SEQ ID NO:5 of WO2018 / 193121) is the amino acid sequence of a modified nomacopan, wherein SEQ ID NO:4 is modified to change Met114 to Gln, Met116 to Gln, Leu117 to Ser, Asp118 to Asn, Ala119 to Gly, Gly120 to Ser, Gly121 to Ala, Leu122 to Asp, Glu123 to Asp, and Val124 to Lys. (nomacopan variant 1)
[0167] SEQ ID NO:23 (SEQ ID NO:6 of WO2018 / 193121) is the amino acid sequence of a modified nomacopan, wherein SEQ ID NO:4 is modified to change Ala44 to Asn, Met116 to Gln, Leu117 to Ser, Gly121 to Ala, Leu122 to Asp, Glu123 to Ala, and Asp149 to Gly. (nomacopan variant 2)
[0168] SEQ ID NO:24 (SEQ ID NO:7 of WO2018 / 193121) is the amino acid sequence of a modified nomacopan, wherein SEQ ID NO:4 is modified to change Ala44 to Asn, Met116 to Gln, Leu122 to Asp, and Asp149 to Gly. (nomacopan variant 3)
[0169] SEQ ID NO: 25 (SEQ ID NO: 8 of WO2018 / 193121) is the amino acid sequence of a modified nomacopan, wherein SEQ ID NO: 4 is modified to change Ala44 to Asn. (nomacopan variant 4).
[0170] In some preferred embodiments, a modified nomacopan polypeptide that exhibits reduced ability to bind to C5 may not exhibit detectable binding to C5 compared to an unmodified nomacopan polypeptide.
[0171] C5 binding may be reduced by at least 2, 5, 10, 15, 20, 50, 100-fold or eliminated, for example relative to the binding exhibited by the unmodified nomacopan polypeptide in SEQ ID NO:4.
[0172] In some embodiments, C5 binding is reduced by at least 50%, 60%, 70%, 80%, 90% or 95% relative to the unmodified nomacopan polypeptide of SEQ ID NO:4.
[0173] The polypeptide may bind C5 with a KD greater than 1 micromolar as determined by surface plasmon resonance, for example, as described in
[49] or as set out in Example 2 of WO2018193121, and / or may inhibit sheep erythrocyte lysis by less than 10% when present in pooled normal whole serum at a concentration of 0.02 mg / mL, wherein a CH50 lysis assay is performed according to or analogously to that performed in
[50] . The ability of the polypeptide to bind C5 may also be determined by measuring the ability of an agent to inhibit complement activation in serum.
[0174] In certain preferred embodiments, variant 2 is used.
[0175] These molecules are examples of molecules that are functional variants of nomacopan, which share the ability to bind LTB4 but do not bind C5 or have reduced binding to C5.
[0176] Thus, a functional equivalent of nomacopan can be a homologue or fragment of nomacopan that (i) retains the ability of nomacopan to bind to C5 and prevent the cleavage of C5 into C5a and C5b by C5 convertase, and / or (ii) retains the ability of nomacopan to bind to LTB4. In certain embodiments, the functional equivalent has properties (i) and (ii). In other embodiments, the functional equivalent has property (ii), but has reduced binding to C5 or no binding to C5 (e.g., one of nomacopan variants 1 to 4).
[0177] In some embodiments, the agent of the present invention is derived from a blood-sucking arthropod. The term "blood-sucking arthropod" includes all arthropods that suck blood from a suitable host, such as insects, ticks, lice, fleas and mites. Preferably, the agent is derived from a tick, preferably from Ornithodoros pubescens.
[0178] Homologs include paralogs and orthologs of the nomacopan sequences specifically identified in Figure 2, including, for example, nomacopan protein sequences from other tick species including: Rhipicephalus appendiculatus, R. sanguineus, R. bursa, A. americanum, A. cajennense, A. hebraeum, Boophilus microplus, B. annulatus, B. decoloratus, Dermacentor reticulatus, D. andersoni, D. marginatus, D. variabilis, Haemaphysalis inermis, Ha.leachii, Ha.punctata, Hyalomma anatolicum anatolicum, Hy.dromedarii, Hy.marginatum marginatum, Ixodes ricinus, I.persulcatus, I.scapularis, I.hexagonus, Argas persicus, A.reflexus, Ornithodoros erraticus, O.moubata moubata, Omporcinus and O.savignyi.
[0179] The term "homolog" is also intended to include equivalent nomacopan protein sequences from mosquito species, including Culex, Anopheles, and Aedes species, particularly Culex quinquefasciatus, Aedes aegypti, and Anopheles gambiae; flea species, such as Ctenocephalides felis (cat flea); horseflies; sandflies; blackflies; tsetse flies; lice; mites; leeches; and flatworms. The native nomacopan protein is thought to exist in three additional forms of about 18 kDa in the tick Ornithodoros pubescens, and the term "homolog" is intended to include these alternative forms of nomacopan.
[0180] Methods for identifying homologues of the nomacopan sequence given in Figure 2 will be clear to those skilled in the art. For example, homologues may be identified by homology searches of public and private sequence databases. Suitably, publicly available databases may be used, but private or commercial databases are equally useful, particularly if they contain data not shown in the public databases. Primary databases are sites where primary nucleotide or amino acid sequence data are deposited and may be publicly available or commercially available. Examples of publicly available master databases include the GenBank database (http: / / www.ncbi.nlm.nih.gov / ), the EMBL database (http: / / www.ebi.ac.uk / ), the DDBJ database (http: / / www.ddbj.nig.ac.jp / ), the SWISS-PROT protein database (http: / / expasy.hcuge.ch / ), PIR (http: / / pir.georgetown.edu / ), TrEMBL (http: / / www.ebi.ac.uk / ), the TIGR database (see http: / / www.tigr.org / tdb / index.html), the NRL-3D database (http: / / www.nbrfa.georgetown.edu), the Protein Data Bank (http: / / www. Base) (http: / / www.rcsb.org / pdb), NRDB database (ftp: / / ncbi.nlm.nih.gov / pub / nrdb / README), OWL database (http: / / www.biochem.ucl.ac.uk / bsm / dbbrowser / OWL / ), and auxiliary databases PROSITE (http: / / expasy.hcuge.ch / sprot / prosite.html), PRINTS (http: / / iupab.leeds.ac.uk / bmb5dp / prints.html), Profiles (http: / / ulrec3.unil.ch / software / PFSCAN_form.html), Pfam (http: / / www.sanger.ac.uk / software / pfam), Identify (http: / / dna.stanford.edu / identify / ) and Blocks (http: / / www.blocks.fhcrc.org) databases.Examples of commercial or proprietary databases include PathoGenome (Genome Therapeutics, Inc.) and PathoSeq (formerly Incyte Pharmaceuticals, Inc.).
[0181] Typically, an identity of greater than 30% between two polypeptides (preferably over a specified region, such as an active site) is considered to indicate functional equivalence and thus that the two proteins are homologous. Preferably, proteins that are homologs have a degree of sequence identity of greater than 60% with the nomacopan protein sequence identified in Figure 2 (SEQ ID NO: 2). More preferred homologs have a degree of identity of greater than 70%, 80%, 90%, 95%, 98% or 99%, respectively, with the nomacopan protein sequence given in Figure 2 (SEQ ID NO: 2). The percent identity as referred to herein is determined using BLAST version 2.1.3 using the default parameters [Blosum 62 matrix; Gap open penalty = 11 and Gap extension penalty = 1] as specified by the National Center for Biotechnology Information (NCBI; http: / / www.ncbi.nlm.nih.gov / ). The % identity can be over the entire length of the relevant reference sequence (eg, amino acids 1-168 of SEQ ID NO: 2 or amino acids 19-168 of SEQ ID NO: 2).
[0182] A nomacopan-type protein can thus be described by reference to a certain % amino acid sequence identity to a reference sequence, e.g., amino acids 19 to 168 of SEQ ID NO: 2 of Figure 2 or amino acids 1 to 168 of SEQ ID NO: 2 of Figure 2, e.g., as a protein comprising or consisting of a sequence having at least 60%, 70%, 80%, 90%, 95%, 98% or 99% identity to amino acids 19 to 168 of SEQ ID NO: 2 of Figure 2 or amino acids 1 to 168 of SEQ ID NO: 2 of Figure 2), where the nomacopan-type protein comprises such a sequence, the nomacopan-type protein can be a fusion protein (with, e.g., a second protein, e.g., a heterologous protein). Suitable second proteins are discussed below.
[0183] In various aspects and embodiments of the present disclosure, the modified nomacopan polypeptide (e.g., nomacopan-type protein) may differ from the unmodified nomacopan polypeptide in SEQ ID NO: 2 and SEQ ID NO: 4 by 1 to 50, 2-45, 3-40, 4-35, 5-30, 6-25, 7-20, 8-25, 9-20, 10-15 amino acids, at most 1, 2, 3, 4, 5, 7, 8, 9, 10, 20, 30, 40, 50 amino acids. These may be substitutions, insertions or deletions, but are preferably substitutions. In the case of deletions, these are preferably deletions of at most 1, 2, 3, 4, 5, 7 or 10 amino acids (e.g., N-terminal or C-terminal deletions). Thus, mutants include proteins containing amino acid substitutions, such as conservative amino acid substitutions that do not affect the function or activity of the protein in an adverse manner. This term is also intended to include natural biological variants (e.g., allelic variants or geographic variants within the species from which the nomacopan protein is derived). Mutants with improved ability to bind wild-type C5 and / or C5 and / or LTB4 from subjects with C5 polymorphisms that render treatment with eculizumab ineffective, or that reduce the efficacy of eculizumab treatment, can also be designed by systematic or directed mutagenesis of specific residues in the protein sequence.
[0184] These modifications can be made to the nomacopan polypeptides as shown in SEQ ID NO:2 and SEQ ID NO:4, and the molecules will remain useful and will be considered functional variants, provided that the resulting modified nomacopan polypeptides retain (i) LTB4 binding activity and / or (ii) C5 binding comparable to the nomacopan polypeptides as shown in SEQ ID NO:2 and SEQ ID NO:4, which can be determined, for example, using the assays mentioned elsewhere herein (e.g., binding to one or both of these is at least 80%, 85%, 90%, 95% compared to binding of the unmodified nomacopan polypeptide). As discussed elsewhere herein, both nomacopan and L-nomacopan have been shown to be effective in the treatment of a mouse model of autoimmune uveitis. L-nomacopan binds LTB4 but not C5. Nomacopan-like proteins can be defined by reference to their ability to bind C5 and / or their ability to bind LTB4. Those that bind LTB4 are particularly useful in the present invention. Those that bind LTB4 and C5 are also particularly useful in the present invention.
[0185] Given the requirement for functional variants to bind to LTB4 and optionally also C5, certain residues should be excluded from modification when modifications are made. These include conserved cysteine residues.
[0186] Other residues should be excluded from modification, or if substituted, should only undergo conservative modifications. These are the LTB4 binding residues. In embodiments where the functional variant binds both LTB4 and C5, then the C5 binding residues as defined below should also preferably be excluded from modification, or if substituted, should preferably only undergo conservative modifications. Given that LTB4 and C5 binding is relatively well understood, it is possible to design a molecule that may have a percent identity of about 65% with nomacopan but where changes are limited to residues not involved in LTB4 binding and optionally also C5 binding.
[0187] For LTB4 binding variants, in some embodiments, each of the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of the mature nomacopan molecule (e.g., as set forth in SEQ ID NO:4, which corresponds to residues 19 to 168 of the full-length protein including the signal sequence) is retained, and at least five, ten, or fifteen or each of the LTB4 binding residues set forth below are retained or undergo conservative modification.
[0188] For LTB4 binding variants, in some embodiments, each of the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of SEQ ID NO:4 is retained, and at least five, ten or fifteen or each of the LTB4 binding residues is retained or undergoes conservative modification, wherein at most 2, 3, 4, 5, 10, 15, 20 of the LTB4 binding residues set forth below undergo conservative modification.
[0189] For LTB4 binding variants, in some embodiments, each of the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of SEQ ID NO:4 is retained, and at least five, ten or fifteen or each of the LTB4 binding residues set forth below is retained.
[0190] For LTB4 binding variants, in some embodiments, each of the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of SEQ ID NO:4 is retained, and each of the LTB4 binding residues set forth below is retained or undergoes conservative modification.
[0191] For LTB4 binding variants, in some embodiments, each of the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of SEQ ID NO:4 is retained, and each of the LTB4 binding residues stated below is retained or undergoes conservative modification, wherein at most 2, 3, 4, 5, 10, 15, 20 of the LTB4 binding residues undergo conservative modification.
[0192] For LTB4 binding variants, in some embodiments, each of the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of SEQ ID NO:4 is retained, and each of the LTB4 binding residues set forth below is retained.
[0193] For variants that bind C5 and LTB4, in some embodiments, each of the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of the mature nomacopan molecule (e.g., as set forth in SEQ ID NO:4, which corresponds to residues 19 to 168 of the full-length protein including the signal sequence) is retained, and at least five, ten, or fifteen, or each of the LTB4 binding residues is retained or undergoes conservative modification, and at least five, ten, or fifteen, or twenty, or each of the C5 binding residues set forth below is retained or undergoes conservative modification.
[0194] For variants that bind to C5 and LTB4, each of the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of SEQ ID NO:4 is retained, and at least five, ten or fifteen or each of the LTB4 binding residues and at least five, ten or fifteen or twenty or each of the C5 binding residues stated below are retained or undergo conservative modification, wherein at most 2, 3, 4, 5, 10, 15, 20 of the LTB4 and C5 binding residues undergo conservative modification.
[0195] For variants that bind to C5 and LTB4, in some embodiments, each of the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of SEQ ID NO:4 is retained, and at least five, ten or fifteen or each of the LTB4 binding residues and at least five, ten or fifteen or twenty or each of the C5 binding residues stated below are retained.
[0196] For variants that bind to C5 and LTB4, in some embodiments, each of the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of SEQ ID NO:4 is retained, and each of the LTB4 binding residues and each of the C5 binding residues stated below is retained or undergoes conservative modification.
[0197] For variants that bind to C5 and LTB4, in some embodiments, each of the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of SEQ ID NO:4 is retained, and each of the LTB4 binding residues and each of the C5 binding residues stated below is retained or undergoes conservative modification, wherein at most 2, 3, 4, 5, 10, 15, 20 of the C5 and / or LTB4 binding residues undergo conservative modification.
[0198] For variants that bind C5 and LTB4, in some embodiments, each of the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of SEQ ID NO:4 is retained, and each of the LTB4 binding residues and each of the C5 binding residues stated below are retained.
[0199] Modifications made outside of these regions may be conservative or non-conservative.
[0200] In each of these embodiments, the spacing between the six cysteine amino acid residues is preferably maintained to maintain the overall structure of the molecule (e.g., the molecule comprises six cysteine residues spaced relative to each other at distances of 32 amino acids apart, 62 amino acids apart, 28 amino acids apart, 1 amino acid apart, and 21 amino acids apart, as arranged from the amino terminus to the carboxyl terminus of the sequence of amino acids 1 to 168 according to the amino acid sequence in Figure 2).
[0201] LTB4 binding residues
[0202] The residues believed to be involved in binding to LTB4 and which are preferably retained in unmodified form or undergo only conservative changes in the sequence of any molecule modified relative to SEQ ID NO: 2 or SEQ ID NO: 4 are Phe18, Tyr25, Arg36, Leu39, Gly41, Pro43, Leu52, Val54, Met56, Phe58, Thr67, Trp69, Phe71, Gln87, Arg89, His99, His101, Aspl03 and Trpl15 (numbering according to SEQ ID NO: 4).
[0203] C5 binding residues
[0204] Residues believed to be involved in binding to C5 that may be retained in unmodified form in the sequence of any molecule modified relative to SEQ ID NO: 2 or SEQ ID NO: 4 are Val26, Val28, Arg29, Ala44, Gly45, Gly61, Thr62, Ser97, His99, His101, Met 114, Met 116, Leu117, Aspl18, Ala119, Gly120, Gly121, Leu122, Glu123, Val124, Glu125, Glu127, His146, Leu147 and Asp 149 (numbering according to SEQ ID NO: 4). These residues are among those modified in nomacopan variants that bind LTB4 but have been modified to reduce binding to C5.
[0205] LTB4 and / or C5 binding residues
[0206] There are two histidine residues, His99 and His101, that are involved in the binding of LTB4 and C5. Thus, the list of residues involved in LTB4 and / or C5 binding is Phe18, Tyr25, Val26, Val28, Arg29, Arg36, Leu39, Gly41, Pro43, Ala44, Gly45, Leu52, Val54, Met56, Phe58, Gly61, Thr62, Thr67, Trp69, Phe71, Gln87, Arg89, Ser97, His99, His101, Asp103, Met 114, Trp115, Met 116, Leu117, Asp118, Ala119, Gly120, Gly121, Leu122, Glu123, Val124, Glu125, Glu127, His146, Leu147, and Asp148. 149 (numbering according to SEQ ID NO: 4).
[0207] Other Examples of Molecules That Bind LTB4 but Exhibit Reduced or No Binding to C5
[0208] As discussed above, nomacopan-type proteins that do not bind to C5 or exhibit reduced binding to C5 but do retain LTB-4 binding activity are disclosed, for example, in WO2018 / 193121, the entire contents of which are incorporated herein by reference. The nomacopan-type proteins having reduced or no C5 binding activity but retaining LTB-4 binding ability can be used in all aspects of the present invention.
[0209] Four exemplary nomacopan-type proteins with reduced or no C5 binding activity but retaining LTB-4 binding ability are disclosed in WO2018 / 193121, specifically, proteins having amino acid sequences as shown in SEQ ID NO: 22 (SEQ ID NO: 5 of WO2018 / 193121, variant 1), SEQ ID NO: 23 (SEQ ID NO: 6 of WO2018 / 193121, variant 2), SEQ ID NO: 24 (SEQ ID NO: 7 of WO2018 / 193121, variant 3) and SEQ ID NO: 25 (SEQ ID NO: 8 of WO2018 / 193121, variant 4). L-nomacopan is referred to as variant 2 in the present examples.
[0210] The protein is a nomacopan-type protein and is therefore considered a functional equivalent of nomacopan, however it only shares its LTB4 binding properties with reduced or no binding to C5.
[0211] The nomacopan-type proteins as defined in WO2018 / 193121 are described in more detail below and can be used in the present invention.
[0212] These proteins with reduced or no C5 binding activity but retaining LTB-4 binding ability may comprise or consist of the following sequence:
[0213] SEQ ID NO:22 (SEQ ID NO:5 of WO2018 / 193121) is the amino acid sequence of a modified nomacopan, wherein SEQ ID NO:4 is modified to change Met114 to Gln, Met116 to Gln, Leu117 to Ser, Asp118 to Asn, Ala119 to Gly, Gly120 to Ser, Gly121 to Ala, Leu122 to Asp, Glu123 to Asp, and Val124 to Lys. (nomacopan variant 1)
[0214] SEQ ID NO:23 (SEQ ID NO:6 of WO2018 / 193121) is the amino acid sequence of modified Coversin, wherein SEQ ID NO:4 is modified to change Ala44 to Asn, Met116 to Gln, Leu117 to Ser, Gly121 to Ala, Leu122 to Asp, Glu123 to Ala, and Asp149 to Gly. (nomacopan variant 2)
[0215] SEQ ID NO:24 (SEQ ID NO:7 of WO2018 / 193121) is the amino acid sequence of modified Coversin, wherein SEQ ID NO:4 is modified to change Ala44 to Asn, Met116 to Gln, Leu122 to Asp, and Asp149 to Gly. (nomacopan variant 3)
[0216] SEQ ID NO:25 (SEQ ID NO:8 of WO2018 / 193121) is the amino acid sequence of modified Coversin, wherein SEQ ID NO:4 is modified to change Ala44 to Asn. (nomacopan variant 4)
[0217] SEQ ID NO: 26 (SEQ ID NO: 9 of WO2018 / 193121) is the amino acid sequence of the loop between βH and α2 at amino acid positions 114 to 124 of SEQ ID NO: 4 (amino acid positions 132-142 of SEQ ID NO: 2).
[0218] SEQ ID NO:27 (SEQ ID NO:10 of WO2018 / 193121) is the amino acid sequence of the loop between βH and α2 at amino acid positions 114 to 124 of SEQ ID NO:4 in nomacopan variant 1 (SEQ ID NO:22).
[0219] SEQ ID NO:28 (SEQ ID NO:11 of WO2018 / 193121) is the amino acid sequence of the loop between βH and α2 at amino acid positions 114 to 124 of SEQ ID NO:4 in nomacopan variant 2 (SEQ ID NO:23).
[0220] SEQ ID NO:29 (SEQ ID NO:12 of WO2018 / 193121) is the amino acid sequence of the loop between βH and α2 at amino acid positions 114 to 124 of SEQ ID NO:4 in nomacopan variant 3 (SEQ ID NO:24).
[0221] A nomacopan-type polypeptide having reduced or no C5 binding activity but retaining LTB-4 binding ability may be described as a modified nomacopan polypeptide (e.g., it has leukotriene or hydroxyeicosanoid binding activity and reduced or absent binding to C5). Reference to a "modified nomacopan polypeptide" is to be understood as a reference to SEQ ID NO: 2 or SEQ ID NO: 4, i.e., a modified form of a nomacopan polypeptide with or without the 18 amino acid signal sequence found at the N-terminus of SEQ ID NO: 2. Thus, it may be considered a nomacopan-type protein.
[0222] The polypeptide may have leukotriene or hydroxyeicosanoid binding activity and reduced or absent binding to C5 and may comprise SEQ ID NO:4 in which 1 to 30 amino acid substitutions occur, wherein
[0223] (i) one or more of the following substitutions (a)-(j) occur at positions 114 to 124 of SEQ ID NO:4:
[0224] a.Met114 is replaced by Gln, Asp, Asn, Glu, Arg, Lys, Gly, Ala, Pro, His or Thr;
[0225] b. Met116 is replaced by Gln, Asp, Asn, Glu, Arg, Lys, Gly, Ala, Pro, His or Thr;
[0226] c. Leu117 is replaced by Ser, Asp, Asn, Glu, Arg, Lys, Gly, Ala or Pro;
[0227] d. Asp118 is replaced by Asn, Gln, Arg, Lys, Gly, Ala, Leu, Ser, Ile, Phe, Tyr, Met Pro, His or Thr;
[0228] e. Ala119 is replaced by Gly, Asp, Asn, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His;
[0229] f. Gly120 is replaced by Ser, Asp, Asn, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His;
[0230] g. Gly121 is replaced by Ala, Asp, Asn, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His;
[0231] h.Leu122 is replaced by Asp, Glu, Asn, Ala, Gln, Arg, Lys, Pro or His;
[0232] i.Glu123 is replaced by Asp, Ala, Gln, Asn, Arg, Lys, Gly, Leu, Ser, Ile, Phe, Tyr, Pro, His or Thr;
[0233] j. Val124 is replaced by Lys, Gln, Asn, Arg, Lys, Gly, Ala, Pro, His or Thr; or / and wherein
[0234] (ii) Ala44 in SEQ ID NO:4 is replaced by Asn, Asp, Gln, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His;
[0235] or a fragment thereof wherein up to five amino acids are deleted from the N-terminus of the modified nomacopan polypeptide.
[0236] As used herein, LK / E binding activity refers to the ability to bind leukotrienes and hydroxyeicosanoids, including but not limited to LTB4, B4 isoleukotrienes and any hydroxylated derivatives thereof, HETE, HPETE, and EET. LTB4 binding is of particular interest.
[0237] The modified nomacopan polypeptide having reduced or no C5 binding activity but retaining LTB-4 binding ability may consist of or may comprise SEQ ID NO: 2 or 4 modified as described below.
[0238] The nomacopan polypeptides in SEQ ID NO:2 and SEQ ID NO:4 have a loop between βH and α2 at amino acid positions 114 to 124 of SEQ ID NO:4 (amino acid positions 132-142 of SEQ ID NO:2). This loop has the sequence shown below:
[0239] -Met-Trp-Met-Leu-Asp-Ala-Gly-Gly-Leu-Glu-Val-(SEQ ID NO:26)
[0240] The first Met is at position 114 of SEQ ID NO:4 and at position 132 of SEQ ID NO:2.
[0241] In the modified nomacopan polypeptide having reduced or no C5 binding activity but retaining LTB-4 binding ability, the nomacopan polypeptide of SEQ ID NO:2 or SEQ ID NO:4 is modified so that one or more of the following substitutions (a)-(j) occur at positions 114 to 124 of SEQ ID NO:4:
[0242] a. Met114 is replaced by Gln, Asp, Asn, Glu, Arg, Lys, Gly, Ala, Pro, His or Thr, preferably Gln or Ala;
[0243] b. Met116 is replaced by Gln, Asp, Asn, Glu, Arg, Lys, Gly, Ala, Pro, His or Thr, preferably Gln or Ala;
[0244] c. Leu117 is replaced by Ser, Asp, Asn, Glu, Arg, Lys, Gly, Ala or Pro, preferably Ser or Ala;
[0245] d. Asp118 is replaced by Asn, Gln, Arg, Lys, Gly, Ala, Leu, Ser, Ile, Phe, Tyr, Met Pro, His or Thr, preferably Asn;
[0246] e. Ala119 is replaced by Gly, Asp, Asn, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His, preferably Gly or Asn;
[0247] f. Gly120 is replaced by Ser, Asp, Asn, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His, preferably Ser or Asn;
[0248] g. Gly121 is replaced by Ala, Asp, Asn, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His, preferably Ala or Asn;
[0249] h. Leu122 is replaced by Asp, Glu, Asn, Ala, Gln, Arg, Lys, Pro or His, preferably Asp or Ala;
[0250] i. Glu123 is replaced by Asp, Ala, Gln, Asn, Arg, Lys, Gly, Leu, Ser, Ile, Phe, Tyr, Pro, His or Thr, preferably Asp, Ala, Gln or Asn;
[0251] j. Val124 is replaced by Lys, Gln, Asn, Arg, Lys, Gly, Ala, Pro, His or Thr, preferably Lys or Ala.
[0252] In the modified nomacopan polypeptide having reduced or no C5 binding activity but retaining LTB-4 binding ability, the nomacopan polypeptide in SEQ ID NO:2 or SEQ ID NO:4 may be modified such that one or more of the following substitutions (a)-(j) occur at positions 114 to 124 of SEQ ID NO:4:
[0253] a.Met114 was replaced by Gln;
[0254] b.Met116 was replaced by Gln;
[0255] c.Leu117 was replaced by Ser;
[0256] d. Asp118 was replaced by Asn;
[0257] e.Ala119 was replaced by Gly;
[0258] f. Gly120 is replaced by Ser;
[0259] g. Gly121 was replaced by Ala;
[0260] h.Leu122 was replaced by Asp;
[0261] i.Glu123 is replaced by Asp or Ala;
[0262] j.Val124 was replaced by Lys.
[0263] In the modified nomacopan polypeptide, two, three, four, five, six, seven, eight, nine or ten of substitutions (a)-(j) are present. Preferably, two or more, five or more or eight or more of substitutions (a)-(j) are present.
[0264] In a modified nomacopan polypeptide having reduced or no C5 binding activity but retaining LTB-4 binding ability, the nomacopan polypeptide in SEQ ID NO:2 or SEQ ID NO:4 may be modified such that the following substitutions are present at positions 114 to 124 of SEQ ID NO:4:
[0265] a.Met114 was replaced by Gln;
[0266] b.Met116 was replaced by Gln;
[0267] c.Leu117 was replaced by Ser;
[0268] d. Asp118 was replaced by Asn;
[0269] e.Ala119 was replaced by Gly;
[0270] f. Gly120 is replaced by Ser;
[0271] g. Gly121 was replaced by Ala;
[0272] h.Leu122 was replaced by Asp;
[0273] i.Glu123 was replaced by Asp;
[0274] j.Val124 was replaced by Lys.
[0275] Optionally, in the modified nomacopan polypeptides mentioned above, Trp 115 is not substituted. A preferred modified nomacopan polypeptide has a loop between βH and α2 at amino acid positions 114 to 124 of SEQ ID NO: 4 having the sequence Gln-Trp-Gln-Ser-Asn-Gly-Ser-Ala-Asp-Asp-Lys (SEQ ID NO: 27).
[0276] In a modified nomacopan polypeptide having reduced or no C5 binding activity but retaining LTB-4 binding ability, the nomacopan polypeptide may be modified such that the following substitutions are present at positions 114 to 124 of SEQ ID NO:4:
[0277] a. Met116 is replaced by Gln, Asp, Asn, Glu, Arg, Lys, Gly, Ala, Pro, His or Thr, preferably Gln;
[0278] b. Leu117 is replaced by Ser, Asp, Asn, Glu, Arg, Lys, Gly, Ala or Pro, preferably Ser;
[0279] c. Gly121 is replaced by Ala, Asp, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His, preferably Ala;
[0280] d. Leu122 is replaced by Asp, Glu, Asn, Gln, Arg, Lys, Pro or His, preferably Asp;
[0281] e.Glu123 is replaced by Asp, Ala, Gln, Asn, Arg, Lys, Gly, Leu, Ser, Ile, Phe, Tyr, Pro, His or Thr, preferably Asp.
[0282] In a more specific embodiment;
[0283] a.Met116 was replaced by Gln;
[0284] b.Leu117 was replaced by Ser;
[0285] c. Gly121 was replaced by Ala;
[0286] d.Leu122 is replaced by Asp;
[0287] e.Glu123 was replaced by Ala.
[0288] Optionally, in this modified nomacopan polypeptide mentioned above, Trp 115 is not substituted. Optionally, in this embodiment, Met 114, Trp 115, Asp 118, Ala 119, Gly 120 and Val 124 are not substituted or are substituted by conservative substitutions as mentioned elsewhere herein. Preferred modified nomacopan polypeptides with reduced or no C5 binding activity but retaining LTB-4 binding ability have a loop between βH and α2 at amino acid positions 114 to 124 of SEQ ID NO: 4, the loop having the sequence Met-Trp-Gln-Ser-Asp-Ala-Gly-Ala-Asp-Ala-Val (SEQ ID NO: 28).
[0289] In a modified nomacopan polypeptide having reduced or no C5 binding activity but retaining LTB-4 binding ability, the nomacopan polypeptide may be modified such that the following substitutions are present at positions 114 to 124 of SEQ ID NO:4:
[0290] a. Met116 is replaced by Gln, Asp, Asn, Glu, Arg, Lys, Gly, Ala, Pro, His or Thr, preferably Gln;
[0291] b. Leu122 is replaced by Asp, Glu, Asn, Gln, Arg, Lys, Pro or His, preferably Asp;
[0292] In a more specific embodiment;
[0293] a.Met116 was replaced by Gln;
[0294] b.Leu122 is replaced by Asp.
[0295] Optionally, in this modified nomacopan polypeptide mentioned above, Trp 115 is not substituted. Optionally, in this embodiment, Met114, Trp 115, Leu117, Asp118, Ala119, Gly120, Gly121, Glu123 and Val124 are not substituted. A preferred modified nomacopan polypeptide having reduced or no C5 binding activity but retaining LTB-4 binding ability has a loop between βH and α2 at amino acid positions 114 to 124 of SEQ ID NO: 4, the loop having the sequence Met-Trp-Gln-Leu-Asp-Ala-Gly-Gly-Asp-Glu-Val (SEQ ID NO: 29).
[0296] In the modified nomacopan polypeptide having reduced or no C5-binding activity but retaining LTB-4 binding ability, the nomacopan polypeptide can be modified so that Ala44 in SEQ ID NO:4 (Ala62 in SEQ ID NO:2) is replaced by Asn, Asp, Gln, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His.
[0297] In a preferred embodiment, Ala44 in SEQ ID NO:4 is replaced by Asn.
[0298] This substitution at position 44 of SEQ ID NO: 4 (or position 62 of SEQ ID NO: 2) may be made in combination with any other substitutions mentioned herein.
[0299] In another modified nomacopan polypeptide having reduced or no C5 binding activity but retaining LTB-4 binding ability, the nomacopan polypeptide may be modified such that one or more of the following substitutions (a)-(j) are present at positions 114 to 124 of SEQ ID NO:4:
[0300] a. Met114 is replaced by Gln, Asp, Asn, Glu, Arg, Lys, Gly, Ala, Pro, His or Thr, preferably Gln or Ala, for example Gln;
[0301] b. Met116 is replaced by Gln, Asp, Asn, Glu, Arg, Lys, Gly, Ala, Pro, His or Thr, preferably Gln or Ala, for example Gln;
[0302] c. Leu117 is replaced by Ser, Asp, Asn, Glu, Arg, Lys, Gly, Ala or Pro, preferably Ser or Ala, for example Ser;
[0303] d. Asp118 is replaced by Asn, Gln, Arg, Lys, Gly, Ala, Leu, Ser, Ile, Phe, Tyr, Met Pro, His or Thr, preferably Asn;
[0304] e. Ala119 is replaced by Gly, Asp, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His, preferably Gly or Asn, for example Gly;
[0305] f. Gly120 is replaced by Ser, Asp, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His, preferably Ser or Asn, e.g. Ser;
[0306] g. Gly121 is replaced by Ala, Asp, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His, preferably Ala or Asn, for example Ala;
[0307] h. Leu122 is replaced by Asp, Glu, Asn, Gln, Arg, Lys, Pro or His, preferably Asp or Ala, for example Asp;
[0308] i. Glu123 is replaced by Asp, Ala, Gln, Asn, Arg, Lys, Gly, Leu, Ser, Ile, Phe, Tyr, Pro, His or Thr, preferably Asp, Ala, Gln or Asn, e.g. Asp or Ala;
[0309] j. Val124 is replaced by Lys, Gln, Asn, Arg, Lys, Gly, Ala, Pro, His or Thr, preferably Lys or Ala, for example Lys;
[0310] And in addition, Ala44 in SEQ ID NO:4 (Ala62 in SEQ ID NO:2) is replaced by Asn, Asp, Gln, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His, preferably Asn.
[0311] In some modified nomacopan polypeptides having reduced or no C5 binding activity but retaining LTB-4 binding ability, the nomacopan polypeptide can be modified such that the following substitutions are present at positions 114 to 124 of SEQ ID NO:4:
[0312] a.Met116 was replaced by Gln;
[0313] b.Leu117 was replaced by Ser;
[0314] c. Gly121 was replaced by Ala;
[0315] d.Leu122 is replaced by Asp;
[0316] e.Glu123 was replaced by Ala;
[0317] And Ala44 in SEQ ID NO:4 is replaced by Asn.
[0318] In a preferred aspect of this embodiment, the amino acid residues corresponding to positions 114 to 124 of SEQ ID NO:4 are as shown in SEQ ID NO:28.
[0319] In some modified nomacopan polypeptides having reduced or no C5 binding activity but retaining LTB-4 binding ability, the nomacopan polypeptide is modified such that the following substitutions are present at positions 114 to 124 of SEQ ID NO:4:
[0320] a.Met116 was replaced by Gln;
[0321] b.Leu122 is replaced by Asp;
[0322] and Ala44 in SEQ ID NO:4 is replaced by Asn
[0323] In a preferred aspect of this embodiment, the amino acid residues corresponding to positions 114 to 124 of SEQ ID NO:4 are as shown in SEQ ID NO:29.
[0324] In some modified nomacopan polypeptides having reduced or no C5 binding activity but retaining LTB-4 binding ability, the Coversin polypeptide may be modified such that Asp149 in SEQ ID NO: 4 is replaced by Gly, Gln, Asn, Ala, Met, Arg, Lys, Leu, Ser, Ile, Phe, Tyr, Pro, His or Thr. In some embodiments, the nomacopan polypeptide is modified such that Asp149 of SEQ ID NO: 4 is replaced by Gly. This substitution at position 149 of SEQ ID NO: 4 (position 167 of SEQ ID NO: 2) may be performed in combination with any other substitutions mentioned herein.
[0325] In some modified nomacopan polypeptides having reduced or no C5 binding activity but retaining LTB-4 binding ability, the nomacopan polypeptide can be modified such that the following substitutions are present at positions 114 to 124 of SEQ ID NO:4:
[0326] a.Met116 was replaced by Gln;
[0327] b.Leu117 was replaced by Ser;
[0328] c. Gly121 was replaced by Ala;
[0329] d.Leu122 is replaced by Asp;
[0330] e.Glu123 was replaced by Ala;
[0331] Ala44 in SEQ ID NO:4 is replaced by Asn and Asp149 in SEQ ID NO:4 is replaced by Gly149.
[0332] In a preferred aspect of this embodiment, the amino acid residues corresponding to positions 114 to 124 of SEQ ID NO:4 are as shown in SEQ ID NO:28.
[0333] In some modified nomacopan polypeptides having reduced or no C5 binding activity but retaining LTB-4 binding ability, the nomacopan polypeptide can be modified such that the following substitutions are present at positions 114 to 124 of SEQ ID NO:4:
[0334] a.Met116 was replaced by Gln;
[0335] b.Leu122 is replaced by Asp;
[0336] Ala44 in SEQ ID NO:4 is replaced by Asn and Asp149 in SEQ ID NO:4 is replaced by Gly149.
[0337] In a preferred aspect of this embodiment, the amino acid residues corresponding to positions 114 to 124 of SEQ ID NO:4 are as shown in SEQ ID NO:29.
[0338] In various aspects and embodiments of the present disclosure, the modified nomacopan polypeptide having reduced or no C5 binding activity but retaining LTB-4 binding ability differs from the unmodified nomacopan polypeptide in SEQ ID NO: 2 and SEQ ID NO: 4 by 1 to 30 amino acids. Any modification may be made to the nomacopan polypeptide in SEQ ID NO: 2 and SEQ ID NO: 4, provided that the resulting modified nomacopan polypeptide exhibits reduced or absent LK / E binding activity and binding to C5 compared to the unmodified nomacopan polypeptide.
[0339] In some embodiments, the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of SEQ ID NO: 4 are retained in the modified nomacopan polypeptides of the invention.
[0340] In some modified nomacopan polypeptides, Asn60 and Asn84 in SEQ ID NO: 4 are each replaced by Gln. This modification can be made by site-directed mutagenesis to prevent N-linked hyperglycosylation when the polypeptide is expressed in yeast.
[0341] In some modified nomacopan polypeptides, one or more of the following amino acids in SEQ ID NO: 4 are believed to be involved in binding to LTB4 and thus may be retained in an unmodified form: Phe18, Tyr25, Arg36, Leu39, Gly41, Pro43, Leu52, Val54, Met56, Phe58, Thr67, Trp69, Phe71, Gln87, Arg89, His99, His101, Aspl03, and Trpl 15. In some modified nomacopan polypeptides, at least five, ten, or fifteen, or all of these amino acids are retained in an unmodified form in the modified nomacopan polypeptides of the invention. In some modified nomacopan polypeptides having reduced or no C5 binding activity but retaining LTB-4 binding ability, one or more of these amino acids may be conservatively substituted. In some modified nomacopan polypeptides having reduced or no C5 binding activity but retaining LTB-4 binding ability, up to five, ten, or fifteen, or all of these amino acids are conservatively substituted in the modified nomacopan polypeptides of the invention.
[0342] The amino acids at the following positions in SEQ ID NO:4 are highly conserved between nomacopan and TSGP2 and TSGP3: 5, 6, 11, 13-15, 20-21, 24-27, 29-32, 35-41, 45, 47-48, 50, 52-60, 64, 66, 69-81, 83, 84, 86, 90-94, 97-104, 112-113, 115, 125-129, 132-139, 145, 148, and 150.
[0343] The amino acids at the following positions in SEQ ID NO:4 are believed to be involved in binding to LTB4 and / or are highly conserved between nomacopan and TSGP2 and TSGP3: 5, 6, 11, 13-15, 18, 20-21, 24-27, 29-32, 35-41, 43, 45, 47-48, 50, 52-60, 64, 66, 67, 69-81, 83, 84, 86, 87, 89, 90-94, 97-104, 112-113, 115, 125-129, 132-139, 145, 148 and 150.
[0344] The amino acids at the following positions in SEQ ID NO:4 are believed to be involved in binding to LTB4 and / or are highly conserved between nomacopan and TSGP2 and TSGP3: 5, 6, 11, 13-15, 18, 20-21, 24-25, 27, 30-32, 35-41, 43, 47-48, 50, 52-60, 64, 66, 67, 69-81, 83, 84, 86, 87, 89, 90-94, 98, 100, 102-104, 112-113, 115, 126, 128-129, 132-139, 145, 148, and 150.
[0345] In some modified nomacopan polypeptides having reduced or no C5 binding activity but retaining LTB-4 binding ability, the above amino acids are therefore retained in unmodified form. In some embodiments, at least five, ten, or fifteen, or all of these amino acids are retained in unmodified form in the modified nomacopan polypeptides of the invention. In some embodiments, one or more of these amino acids may be conservatively substituted. In some embodiments, up to five, ten, or fifteen, twenty, twenty-five, 30, 40, 50, or all of these amino acids are conservatively substituted in the modified nomacopan polypeptides of the invention.
[0346] The modified nomacopan polypeptides referred to herein typically differ from SEQ ID NO: 2 or SEQ ID NO: 4 by 1 to 30, preferably 2 to 25, more preferably 3 to 20, even more preferably 4 to 15 amino acids. Typically, the differences will be 5 to 12, or 6 to 10 amino acid changes. For example, 1 to 30 or 2 to 25, 3 to 30, 4 to 15, 5 to 12 or 6 to 10 amino acid substitutions may be made in SEQ ID NO: 2 or SEQ ID NO: 4.
[0347] A modified nomacopan polypeptide having a loop as shown in SEQ ID NO: 27 between βH and α2 at amino acid positions 114 to 124 of SEQ ID NO: 4 (amino acid positions 132-142 of SEQ ID NO: 2) has 10 amino acid substitutions compared to SEQ ID NO: 4 due to the presence of this loop. In some embodiments, the modified nomacopan polypeptides mentioned herein therefore preferably have 1 to 15, 2 to 10, 3 to 5 or at most 2, 3, 4 or 5 additional substitutions compared to SEQ ID NO: 4 in addition to those shown in SEQ ID NO: 22 (e.g., in the loop of SEQ ID NO: 27).
[0348] A modified nomacopan polypeptide having a loop as shown in SEQ ID NO: 28 between βH and α2 at amino acid positions 114 to 124 of SEQ ID NO: 4 (amino acid positions 132-142 of SEQ ID NO: 2) has 5 amino acid substitutions compared to SEQ ID NO: 4 due to the presence of this loop. In some embodiments, the modified nomacopan polypeptides mentioned herein therefore preferably have 1-20, 2-15, 3-10 or at most 2, 3, 4, 5, 6, 7, 8, 9, 10 additional substitutions compared to SEQ ID NO: 4 in addition to those shown in SEQ ID NO: 23 (e.g. in the loop of SEQ ID NO: 28). Additional substitutions preferably include substitutions at positions 44 and 149 as set out elsewhere herein.
[0349] A modified nomacopan polypeptide having a loop as shown in SEQ ID NO: 29 between βH and α2 at amino acid positions 114 to 124 of SEQ ID NO: 4 (amino acid positions 132-142 of SEQ ID NO: 2) has 2 amino acid substitutions compared to SEQ ID NO: 4 due to the presence of this loop. In some embodiments, the modified nomacopan polypeptide therefore preferably has 1 to 25, 2 to 12, 3 to 15 or at most 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 additional substitutions compared to SEQ ID NO: 4 in addition to those shown in SEQ ID NO: 24 (e.g., substitutions in the loop of SEQ ID NO: 29). Additional substitutions preferably include substitutions at positions 44 and 149 as set out elsewhere herein.
[0350] A modified nomacopan polypeptide having a substitution at position 44 of SEQ ID NO: 4 as set out elsewhere herein preferably has 1 to 25, 2 to 12, 3 to 15, or at most 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 additional substitutions compared to SEQ ID NO: 4.
[0351] Substitutions other than those explicitly mentioned above are preferably conservative substitutions, for example according to the following table. Amino acids in the same box in the second column and preferably in the same row in the third column may substitute for each other:
[0352]
[0353] A preferred modified nomacopan polypeptide having reduced or no C5 binding activity but retaining LTB-4 binding ability may comprise or consist of the amino acid sequence shown in one of SEQ ID NOs: 22, 23, 24, 25.
[0354] Examples of modified nomacopan polypeptides having reduced or no C5 binding activity but retaining LTB-4 binding ability include
[0355] 1. A modified nomacopan polypeptide having leukotriene or hydroxyeicosanoid binding activity and reduced or absent binding to C5, the modified nomacopan polypeptide comprising SEQ ID NO: 4 in which 1 to 30 amino acid substitutions occur, wherein
[0356] (i) one or more of the following substitutions (a)-(j) occur at positions 114 to 124 of SEQ ID NO:4:
[0357] a.Met114 is replaced by Gln, Asp, Asn, Glu, Arg, Lys, Gly, Ala, Pro, His or Thr;
[0358] b. Met116 is replaced by Gln, Asp, Asn, Glu, Arg, Lys, Gly, Ala, Pro, His or Thr;
[0359] c. Leu117 is replaced by Ser, Asp, Asn, Glu, Arg, Lys, Gly, Ala or Pro;
[0360] d. Asp118 is replaced by Asn, Gln, Arg, Lys, Gly, Ala, Leu, Ser, Ile, Phe, Tyr, Met Pro, His or Thr;
[0361] e. Ala119 is replaced by Gly, Asp, Asn, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His;
[0362] f. Gly120 is replaced by Ser, Asp, Asn, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His;
[0363] g. Gly121 is replaced by Ala, Asp, Asn, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His;
[0364] h.Leu122 is replaced by Asp, Glu, Asn, Ala, Gln, Arg, Lys, Pro or His;
[0365] i.Glu123 is replaced by Asp, Ala, Gln, Asn, Arg, Lys, Gly, Leu, Ser, Ile, Phe, Tyr, Pro, His or Thr;
[0366] j. Val124 is replaced by Lys, Gln, Asn, Arg, Lys, Gly, Ala, Pro, His or Thr; or / and wherein
[0367] (ii) Ala44 in SEQ ID NO:3 is replaced by Asn, Asp, Gln, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His;
[0368] or a fragment thereof wherein up to five amino acids are deleted from the N-terminus of the modified nomacopan polypeptide.
[0369] 2. The modified nomacopan polypeptide according to item 1, wherein
[0370] (i) one or more of the following substitutions (a)-(j) occur at positions 114 to 124 of SEQ ID NO:4:
[0371] a.Met114 was replaced by Gln;
[0372] b.Met116 was replaced by Gln;
[0373] c.Leu117 was replaced by Ser;
[0374] d. Asp118 was replaced by Asn;
[0375] e.Ala119 was replaced by Gly;
[0376] f. Gly120 is replaced by Ser;
[0377] g. Gly121 was replaced by Ala;
[0378] h.Leu122 was replaced by Asp;
[0379] i.Glu123 is replaced by Asp or Ala;
[0380] j. Val124 is replaced by Lys; or / and
[0381] (ii) Ala44 in SEQ ID NO:3 is replaced by Asn44;
[0382] or a fragment thereof wherein up to five amino acids are deleted from the N-terminus of the modified nomacopan polypeptide.
[0383] 3. The modified nomacopan polypeptide or fragment thereof according to item 1 or item 2, wherein in positions 114 to 124 of SEQ ID NO: 4, one or more of the substitutions (a) to (j) are present.
[0384] 4. The modified nomacopan polypeptide or fragment thereof according to item 3, wherein two or more of substitutions (a) to (j) are present.
[0385] 5. The modified nomacopan polypeptide or fragment thereof according to item 4, wherein five or more of substitutions (a) to (j) are present.
[0386] 6. The modified nomacopan polypeptide or fragment thereof according to item 5, wherein each of substitutions (a) to (j) is present, optionally wherein Trp 115 is unsubstituted.
[0387] 7. The modified nomacopan polypeptide or fragment thereof according to item 5, wherein each of the substitutions (a) to (j) as defined in item 2 is present, optionally wherein Trp 115 is unsubstituted.
[0388] 8. The modified polypeptide or fragment thereof according to item 7, wherein Glu123 is replaced by Asp.
[0389] 9. The modified nomacopan polypeptide or fragment thereof according to any one of items 1 to 8, which has a loop sequence between amino acid positions 114 to 124 of SEQ ID NO: 4 as shown in SEQ ID NO: 27, and which has 1 to 15 additional substitutions compared to SEQ ID NO: 4 in addition to those shown in SEQ ID NO: 22.
[0390] 10. The modified nomacopan polypeptide or fragment thereof according to item 9, which, in addition to those shown in SEQ ID NO: 22, has 2 to 10 additional substitutions compared to SEQ ID NO: 27.
[0391] 11. The modified nomacopan polypeptide or fragment thereof according to item 9 or 10, which, in addition to those shown in SEQ ID NO: 22, has 3 to 5 additional substitutions compared to SEQ ID NO: 27.
[0392] 12. The modified nomacopan polypeptide according to any one of items 1 to 8, which consists of or comprises SEQ ID NO: 22.
[0393] 13. The modified nomacopan polypeptide or fragment thereof according to any one of items 1 to 5, wherein:
[0394] a. Met116 is replaced by Gln, Asp, Asn, Glu, Arg, Lys, Gly, Ala, Pro, His or Thr, preferably Gln;
[0395] b. Leu117 is replaced by Ser, Asp, Asn, Glu, Arg, Lys, Gly, Ala or Pro, preferably Ser;
[0396] c. Gly121 is replaced by Ala, Asp, Asn, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His, preferably Ala;
[0397] d. Leu122 is replaced by Asp, Glu, Asn, Ala, Gln, Arg, Lys, Pro or His, preferably Asp; and
[0398] e.Glu123 is replaced by Asp, Ala, Gln, Asn, Arg, Lys, Gly, Leu, Ser, Ile, Phe, Tyr, Pro, His or Thr, preferably Ala or Asp.
[0399] 14. The modified nomacopan polypeptide or fragment thereof according to item 13, wherein in positions 114 to 124 of SEQ ID NO: 4:
[0400] a.Met116 was replaced by Gln;
[0401] b.Leu117 was replaced by Ser;
[0402] c. Gly121 was replaced by Ala;
[0403] d. Leu122 is replaced by Asp; and
[0404] e.Glu123 was replaced by Ala.
[0405] 15. The modified nomacopan polypeptide or fragment thereof according to item 13 or item 14, wherein Trp 115 is not substituted.
[0406] 16. The modified nomacopan polypeptide or fragment thereof according to item 13, 14 or 15, wherein Met114, Trp115, Asp118, Ala119, Gly120 and Val124 are not substituted.
[0407] 17. The modified nomacopan polypeptide or fragment thereof according to any one of items 1 to 5 or 13 to 16, which has a loop sequence between amino acid positions 114 to 124 of SEQ ID NO: 4 as shown in SEQ ID NO: 28, and which has 1 to 20 additional substitutions compared to SEQ ID NO: 4 in addition to those shown in SEQ ID NO: 23.
[0408] 18. The modified nomacopan polypeptide or fragment thereof according to item 17, which, in addition to those shown in SEQ ID NO: 23, has 2 to 15 additional substitutions compared to SEQ ID NO: 4.
[0409] 19. The modified nomacopan polypeptide or fragment thereof according to item 17 or 18, which, in addition to those shown in SEQ ID NO: 23, has 3 to 10 additional substitutions compared to SEQ ID NO: 4.
[0410] 20. The modified nomacopan polypeptide according to any of items 1 to 5 or 13 to 16, which consists of or comprises SEQ ID NO: 23.
[0411] 21. The modified nomacopan polypeptide or fragment thereof according to any one of items 1 to 4, wherein:
[0412] a. Met116 is replaced by Gln, Asp, Asn, Glu, Arg, Lys, Gly, Ala, Pro, His or Thr, preferably Gln;
[0413] b. Leu122 is replaced by Asp, Glu, Asn, Ala, Gln, Arg, Lys, Pro or His, preferably Asp.
[0414] 22. The modified nomacopan polypeptide or fragment thereof according to item 21, wherein
[0415] a. Met116 is replaced by Gln; and
[0416] b.Leu122 is replaced by Asp.
[0417] 23. The modified nomacopan polypeptide or fragment thereof according to item 21 or item 22, wherein Trp 115 is not substituted.
[0418] 24. The modified nomacopan polypeptide or fragment thereof according to item 21, 22 or 23, wherein Met114, Trp115, Leu117, Asp118, Ala119, Gly120, Gly121, Glu123 and Val124 are not substituted.
[0419] 25. The modified nomacopan polypeptide or fragment thereof according to any one of items 1 to 4 or 21 to 24, which has a loop sequence between amino acid positions 114 to 124 of SEQ ID NO: 4 as shown in SEQ ID NO: 29, and which has 1 to 25 additional substitutions compared to SEQ ID NO: 4 in addition to those shown in SEQ ID NO: 24.
[0420] 26. The modified nomacopan polypeptide or fragment thereof according to item 25, which, in addition to those shown in SEQ ID NO: 24, has 2 to 12 additional substitutions compared to SEQ ID NO: 4.
[0421] 27. The modified nomacopan polypeptide or fragment thereof according to item 25 or 26, which, in addition to those shown in SEQ ID NO: 24, has 3 to 15 additional substitutions compared to SEQ ID NO: 4.
[0422] 28. The modified nomacopan polypeptide according to any of items 1 to 4 or 21 to 24, which consists of or comprises SEQ ID NO: 24.
[0423] 29. The modified nomacopan polypeptide or fragment thereof according to any one of items 1 to 11 or 13 to 28, wherein Ala44 in SEQ ID NO: 4 is replaced by Asn, Asp, Gln, Glu, Arg, Lys, Leu, Ile, Phe, Tyr, Met, Pro or His.
[0424] 30. The modified nomacopan polypeptide or fragment thereof according to item 29, wherein Ala44 in SEQ ID NO: 4 is replaced by Asn.
[0425] 31. The modified nomacopan polypeptide or fragment thereof according to any one of items 1 to 11 or 13 to 30, wherein Asp149 in SEQ ID NO: 4 is replaced by Gly, Gln, Asn, Ala, Met, Arg, Lys, Leu, Ser, Ile, Phe, Tyr, Pro, His or Thr.
[0426] 32. The modified nomacopan polypeptide according to item 30 or 31, wherein Ala44 in SEQ ID NO: 4 is replaced by Asn and Asp149 in SEQ ID NO: 4 is replaced by Gly.
[0427] 33. A modified nomacopan polypeptide or fragment thereof according to any of the preceding items, wherein the six cysteine amino acids at positions 6, 38, 100, 128, 129, 150 of SEQ ID NO: 4 are retained in unmodified form.
[0428] 34. The modified nomacopan polypeptide according to any of items 1 to 11, 13 to 19 or 21 to 27, wherein Asn60 and Asn84 are each replaced by GIn.
[0429] 35. The modified nomacopan polypeptide or fragment thereof according to any of the preceding items, wherein one or more of the following amino acids are not substituted: Phe18, Tyr25, Arg36, Leu39, Gly41, Pro43, Leu52, Val54, Met56, Phe58, Thr67, Trp69, Phe71, Gln87, Arg89, His99, His101, Asp103 and Trp115.
[0430] 36. The modified nomacopan polypeptide or fragment thereof according to item 35, wherein all of the following amino acids are unsubstituted: Phe18, Tyr25, Arg36, Leu39, Gly41, Pro43, Leu52, Val54, Met56, Phe58, Thr67, Trp69, Phe71, Gln87, Arg89, His99, His101, Asp103 and Trp115.
[0431] 37. The modified nomacopan polypeptide or fragment thereof according to any one of items 1 to 36, wherein:
[0432] a. amino acids 5, 6, 11, 13-15, 20-21, 24-27, 29-32, 35-41, 45, 47-48, 50, 52-60, 64, 66, 69-81, 83, 84, 86, 90-94, 97-104, 112-113, 115, 125-129, 132-139, 145, 148 and 150 in SEQ ID NO: 4 are not substituted; or
[0433] b. amino acids 5, 6, 11, 13-15, 18, 20-21, 24-27, 29-32, 35-41, 43, 45, 47-48, 50, 52-60, 64, 66, 67, 69-81, 83, 84, 86, 87, 89, 90-94, 97-104, 112-113, 115, 125-129, 132-139, 145, 148 and 150 in SEQ ID NO:4 are not substituted; or
[0434] c. Amino acids 5, 6, 11, 13-15, 18, 20-21, 24-25, 27, 30-32, 35-41, 43, 47-48, 50, 52-60, 64, 66, 67, 69-81, 83, 84, 86, 87, 89, 90-94, 98, 100, 102-104, 112-113, 115, 126, 128-129, 132-139, 145, 148 and 150 in SEQ ID NO:4 are not substituted.
[0435] 38. The modified nomacopan polypeptide according to item 1 or item 2, comprising or consisting of the sequence SEQ ID NO: 25.
[0436] 39. A modified nomacopan polypeptide or fragment thereof according to any of the preceding items, which binds to LTB4.
[0437] Snippet
[0438] Functional equivalents of nomacopan include fragments of the nomacopan protein, provided that the fragment retains the ability to: (i) bind to LTB4 and / or (ii) C5 (e.g., wild-type C5 and / or C5 from a subject with a C5 polymorphism that renders treatment with eculizumab ineffective, or reduces the efficacy of eculizumab treatment). Preferably, the functional fragment has properties (i) and (ii). In other preferred embodiments, the functional fragment has property (i) but has reduced or absent binding to C5.
[0439] Fragments may include, for example, polypeptides of less than 150 amino acids, less than 145 amino acids, derived from the nomacopan protein sequence (or homologues), provided that these fragments retain the ability to bind LTB4 and optionally C5.
[0440] Fragments may include, for example, polypeptides of at least 150 amino acids, at least 145 amino acids derived from the nomacopan protein sequence (or homologues), provided that these fragments retain the ability to bind LTB4 and optionally C5.
[0441] Any functional equivalent or fragment thereof preferably retains the pattern of cysteine residues found in nomacopan. For example, the functional equivalent comprises six cysteine residues spaced relative to each other at a distance of 32 amino acids, 62 amino acids, 28 amino acids, 1 amino acid and 21 amino acids apart, as arranged from the amino-terminus to the carboxyl-terminus of the sequence of amino acids 1 to 168 according to the amino acid sequence in Figure 2 (SEQ ID NO:2). Exemplary fragments of the nomacopan protein are disclosed in SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14. DNA encoding the corresponding fragments is disclosed in SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13.
[0442] Included as such fragments are not only fragments of the Ornithodorosus nomacopan protein specifically identified herein in Figure 2, but also fragments of homologues (e.g. variants) of this protein, as described above. Such fragments of homologues will generally have greater than 60% identity with fragments of the nomacopan protein sequence in Figure 2, but more preferred fragments of homologues will exhibit a degree of identity greater than 70%, 80%, 90%, 95%, 98% or 99% with fragments of the nomacopan protein sequence in Figure 2, respectively. Preferably, the fragments will retain the cysteine spacings mentioned above. Of course, fragments with improved properties can be rationally designed by systematically mutating or fragmenting the wild-type sequence followed by appropriate activity assays. Fragments may exhibit similar or greater affinity to nomacopan for LTB4, and optionally similar or greater affinity to nomacopan for C5. These fragments may have the sizes described above for fragments of the nomacopan protein.
[0443] As discussed above, nomacopan-type proteins preferably bind LTB4 and optionally also C5.
[0444] Conservative substitution
[0445] Any substitution is preferably a conservative substitution, for example according to the following table. Amino acids in the same box in the second column and preferably in the same row in the third column may substitute for each other:
[0446]
[0447] Fusion Protein
[0448] The functional equivalent used according to the invention may be a fusion protein obtained, for example, by cloning a polynucleotide encoding a nomacopan protein or a functional equivalent in frame with the coding sequence of a heterologous protein sequence.
[0449] As used herein, the term "heterologous" is intended to indicate any polypeptide other than a nomacopan protein or a functional equivalent thereof. Examples of heterologous sequences that may be included in a soluble fusion protein at the N-terminus or C-terminus are the following: an extracellular domain of a membrane-bound protein, an immunoglobulin constant region (Fc region), PAS or XTEN or similar unstructured polypeptides, a multimerization domain, an extracellular protein domain, a signal sequence, an export sequence, or a sequence that allows purification by affinity chromatography. Many of these heterologous sequences are commercially available as expression plasmids, as these sequences are often included in fusion proteins to provide additional properties without significantly impairing a specific biological activity of the protein to which they are fused
[51] . Examples of such additional properties are a longer half-life in body fluids (e.g. due to the addition of an Fc region or PASylation
[52] ), extracellular localization, or an easier purification procedure, as allowed by a tag such as a histidine, GST, FLAG, avidin, or HA tag. The fusion protein may additionally contain a linker sequence (e.g., 1-50 amino acids in length, such that the components are separated by this linker sequence.
[0450] Fusion proteins are therefore examples of proteins comprising nomacopan-like proteins and include as specific examples proteins comprising a PAS sequence and a nomacopan-type protein sequence. The PAS sequence is described, for example, in
[52] and EP2173890, and the PASylated nomacopan molecule is described in Kuhn et al.
[53] . Describes the genetic fusion of a protein with a conformationally disordered polypeptide sequence consisting of the amino acids Pro, Ala and / or Ser. This is a technology developed by XL Protein (http: / / xl-protein.com / ) and provides a simple way to connect a solvated random chain with a large hydrodynamic volume to the protein to which it is fused. The polypeptide sequence exhibits a random coil structure. Therefore, the apparent molecular weight of the resulting fusion protein is much greater than the actual molecular weight of the fusion protein. This greatly reduces the clearance rate by renal filtration in biological systems. Suitable PAS sequences are described in EP2173890 and
[52] . Any suitable PAS sequence can be used in the fusion protein. Examples include amino acid sequences consisting of at least about 100 amino acid residues that form a random coil conformation and consisting of or consisting essentially of: alanine, serine and proline residues (or consisting of or consisting essentially of: proline and alanine residues). This may comprise a plurality of amino acid repeat sequences, wherein the repeat sequences consist of or consist essentially of: Ala, Ser and Pro residues (or proline and alanine residues), and wherein no more than 6 consecutive amino acid residues are identical. Proline residues may comprise greater than 4% and less than 40% of the amino acids of the sequence. The sequence may comprise an amino acid sequence selected from:
[0451] ASPAAPAPASPAAPAPSAPA(SEQ ID NO:15);
[0452] AAPASPAPAAPSAPAPAAPS (SEQ ID NO: 16);
[0453] APSSSPSAPSSPSPASPSS(SEQ ID NO:17),
[0454] SAPSSPSPSSAPSSPSPASPS(SEQ ID NO:18),
[0455] SSPSAPSPSSPASPSPSSPA (SEQ ID NO:19),
[0456] AASPAAPSAPPAAASPAAPSAPPA (SEQ ID NO: 20) and
[0457] ASAAAPAAASAAASAPSAAA(SEQ ID NO:21)
[0458] Or a circular arrangement or multimer of these sequences in their entirety or of parts of these sequences. For example, one of 5 to 40, 10 to 30, 15 to 25, 18 to 20, preferably 20 to 30 or 30 repeats may be present in the PAS sequence, i.e. one of SEQ ID NOs 15 to 21, preferably a copy of SEQ ID NO: 15. Preferably, the PAS sequence comprises or consists of 30 copies of SEQ ID NO: 15. Preferably, the PAS sequence is fused to the N-terminus of the nomacopan-type protein (directly or via a linker sequence).
[0459] In certain preferred embodiments, the nomacopan-type protein may comprise or consist of amino acids 19 to 168 of SEQ ID NO: 2 (e.g., a fusion protein comprising (a) a PAS sequence consisting of 30 copies of SEQ ID NO: 15 and (b) amino acids 19 to 168 of SEQ ID NO: 2, wherein (a) is fused directly or via a linker sequence to the N-terminus of (b)). Exemplary sequences are provided at Figure 2D and SEQ ID NO:30.
[0460] In another preferred embodiment, the nomacopan-type protein may comprise or consist of SEQ ID NO: 22, 23, 24 or 25 (e.g., a fusion protein comprising (a) a PAS sequence consisting of 30 copies of SEQ ID NO: 15 and (b) SEQ ID NO: 22, 23, 24 or 25, wherein (a) is fused directly or via a linker sequence to the N-terminus of (b)). A preferred form will contain SEQ ID NO: 22. Exemplary sequences are provided at Figure 2E and SEQ ID NO:31.
[0461] The fusion protein can additionally contain a linker sequence (e.g., 1 to 50, 2 to 30, 3 to 20, 5 to 10, 2 to 4, 3 to 5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 amino acids in length) such that the components are separated by the linker sequence. In one embodiment, the linker sequence can be a single alanine residue.
[0462] In the present invention, "PAS-nomacopan" is intended to refer to a functional equivalent of nomacopan that is PASylated, for example as described above, and PAS-L-nomacopan is intended to refer to a functional equivalent of nomacopan that binds to LTB4 instead of C5 and is PASylated. The sequences of the PAS-nomacopan molecules tested in the Examples are Figure 2Dand SEQ ID NO: 30. The sequence of the PAS-L-nomacopan molecule tested in the examples is Figure 2E and SEQ ID NO:31. PAS-nomacopan and PAS-L-nomacopan have the following advantages: they each have a longer half-life, thereby allowing for less frequent administration, which is more convenient for patients. PAS-nomacopan thus combines the advantages of nomacopan in that it inhibits both C5 and LTB4-dependent pathways, but can be administered less frequently than nomacopan, thus providing an administration advantage. PAS-L-nomacopan thus combines the advantages of L-nomacopan in that it inhibits LTB4-dependent pathways without inhibiting C5-dependent pathways, but can be administered less frequently than L-nomacopan, thus providing an administration advantage.
[0463] Preparation of reagents
[0464] The protein and its functional equivalents can be prepared in recombinant form by expression in a host cell. Such expression methods are well known to those skilled in the art and are described in detail by
[54] and
[55] . The recombinant form of the nomacopan protein and its functional equivalents is preferably not glycosylated. Preferably, the host cell is Escherichia coli.
[0465] The nomacopan protein and its functional equivalents are preferably in isolated form, e.g., separated from at least one component of the host cell and / or the cell growth medium in which it is expressed. In some embodiments, the nomacopan protein or its functional equivalent is purified to at least 90%, 95%, or 99% purity, as determined, e.g., by electrophoresis or chromatography. The proteins and fragments of the invention may also be prepared using conventional techniques of protein chemistry. For example, protein fragments may be prepared by chemical synthesis. Methods for producing fusion proteins are standard in the art and will be known to the skilled reader. For example, most general molecular biology, microbiology, recombinant DNA techniques, and immunology techniques can be found in
[54] or
[56] .
[0466] As a reagent for nucleic acid molecules
[0467] According to another embodiment of the invention, the agent may be a nucleic acid molecule encoding a nomacopan-type protein. For example, gene therapy may be used to achieve endogenous production of nomacopan-type proteins by relevant cells in a subject in vivo or ex vivo. Another approach is to administer "naked DNA," in which the therapeutic gene is injected directly into the bloodstream or into muscle tissue.
[0468] Preferably, the nucleic acid molecule comprises or consists of bases 55 to 507 of the nucleotide sequence in Figure 2 (SEQ ID NO: 1). This nucleotide sequence encodes the nomacopan protein in Figure 2 without a signal sequence. The first 54 bases of the nucleotide sequence in Figure 2 encode a signal sequence that is not essential for complement inhibition activity or LTB4 binding activity. Alternatively, the nucleic acid molecule may comprise or consist of bases 1 to 507 of the nucleic acid sequence in Figure 2 that encodes a protein with a signal sequence.
[0469] Mode of administration
[0470] The nomacopan-type protein can be administered directly to the eye or systemically. It is preferably administered directly to the surface of the eye, for example topically (e.g., in the form of drops or ointments) or by direct introduction into the eye (e.g., direct administration within the boundaries of the eye as defined by the sclera). Examples of direct administration within the boundaries of the eye include intravitreal administration and suprachoroidal administration. Intravitreal administration (e.g., intravitreal injection) is well known in the art. Suprachoroidal administration can also be performed.
[0471] Topical application
[0472] The inventors have observed that topical administration of nomacopan-type proteins to the eye affects experimental UAE, which is unexpected because it was not previously thought that such proteins could cross the cornea. As shown in Example 1, in the UAE mouse model used, L-nomacopan, nomacopan, and PAS-nomacopan all reduced clinical scores to some extent. This is consistent with the ability of these molecules to cross the cornea and exert their effects within the eye.
[0473] The fact that nomacopan-type protein topical treatment has efficacy against retinal proliferative diseases, i.e., diseases in which the pathological effects are within the eye, means that any of the nomacopan-type proteins can be used alone in certain embodiments to treat retinal proliferative diseases. In certain embodiments of the invention, the nomacopan-type protein is administered topically, e.g., daily, or 2-5, 3-4 times daily.
[0474] Apply directly into the eye
[0475] It may be advantageous to introduce the agents of the invention directly into the eye, for example, by direct administration within the boundaries of the eye as defined by the sclera. In certain embodiments, the agents of the invention are introduced intravitreally. In other embodiments, the agents of the invention are introduced suprachoroidally.
[0476] In certain embodiments, the agents of the invention are introduced intravitreally. Intravitreal administration is well known in the art. In certain embodiments of the invention, intravitreal administration is performed approximately once every 4 to 6, 4 to 8, 4 to 10 weeks.
[0477] In other embodiments, the agents of the invention are introduced suprachoroidally. The suprachoroidal space (SCS) is the potential space between the sclera and choroid that spans the circumference of the posterior segment of the eye. Introducing agents into the SCS targets the choroid, retinal pigment epithelium, and retina with high bioavailability while maintaining low levels elsewhere in the eye. In fact, Phase III clinical trials are studying the safety and efficacy of SCS drug delivery. The agents can be administered to the SCS, for example, using a hypodermic needle, microneedle, or microvascular stent
[57] . In certain embodiments of the invention, suprachoroidal administration is performed approximately every 4 to 6, 4 to 8, or 4 to 10 weeks.
[0478] Topical application combined with direct application into the eye
[0479] As discussed elsewhere herein, nomacopan-type proteins may also be used in combination with a second agent. In certain embodiments, the second agent is introduced directly into the eye. This has the advantage that it can reduce the frequency with which the second agent needs to be administered directly into the eye. Direct administration into the eye, although generally safe, carries the risk of certain complications (e.g., infection, blockage of a major artery entering the eye, retinal detachment, bleeding in the eye, and damage to the lens in the eye). In addition, this is a medical procedure that requires the patient to go to the hospital. For the treatment of retinal proliferative diseases, the administration may be performed, for example, once every 1 to 2 months. Therefore, it would be advantageous to reduce the frequency with which these administrations are performed.
[0480] Thus, in certain embodiments, a method of treating or preventing a retinal proliferative disease in a subject comprises (i) topically administering a nomacopan-type protein as defined herein and (ii) administering a second retinal proliferative therapy directly into the eye of the subject. The second retinal proliferative therapy may be as defined elsewhere herein, or it may itself be a nomacopan-type protein (e.g., it may be the same nomacopan-type protein as the topically administered nomacopan-type protein, or it may be a second nomacopan-type protein).
[0481] Examples of second retinal proliferative treatments include anti-VEGF agents (e.g., anti-VEGF-A antibodies or fragments thereof, such as bevacizumab (Avastin), ranibizumab (Levofloxacin), anti-VEGF aptamers (e.g., pegaptanib (Magujin)), or another VEGF antagonist, such as aflibercept (Elia, a recombinant fusion protein consisting of the vascular endothelial growth factor (VEGF) binding portion from the extracellular domain of human VEGF receptors 1 and 2 fused to the Fc portion of human IgG1 immunoglobulin), steroids (e.g., corticosteroids), immunomodulatory therapy (IMT) drugs (e.g., methotrexate, azathioprine, or mycophenolate mofetil), biological response modifiers (BRM) drugs (anti-TNFα agents, such as antibodies or fragments thereof that bind TNFα, such as infliximab or adalimumab). Preferably, the second agent is an anti-VEGF agent.
[0482] In embodiments where a nomacopan-type protein is administered topically and a second nomacopan-type protein is administered directly into the eye, the agent administered topically need not be a long-acting protein (e.g., a fusion protein containing a sequence designed to reduce clearance time). Thus, it may, for example, be an agent that is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2), or a functional equivalent of said protein, wherein the length of the protein is at most 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160 amino acids (preferably at most 150 amino acids). For example, it may be an agent that is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2), or a functional equivalent thereof, wherein if said protein is a functional equivalent, it is not a fusion protein (e.g., it may be a homologue of said protein, a fragment of said protein, or a functional equivalent of a fragment of a homologue, wherein homologues are as defined elsewhere herein). In these embodiments, the agent administered directly into the eye may be a functional equivalent of a fusion protein as defined elsewhere herein. For example, the agent administered topically may be a protein consisting of amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2), SEQ ID NO: 22, 23, 24, 25, preferably amino acids 19 to 168 of SEQ ID NO: 2 or SEQ ID NO: 22, and / or the agent administered directly into the eye is a fusion protein comprising (i) amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2), SEQ ID NO: 22, 23, 24, 25, preferably amino acids 19 to 168 of SEQ ID NO: 2 or SEQ ID NO: 22, and (ii) a PAS sequence as defined herein, for example a sequence consisting of 30 copies of SEQ ID NO: 15.
[0483] In other embodiments, an agent that is a protein comprising amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO:2), or a functional equivalent of said protein, is administered topically and a second retinal proliferative disease treatment is administered directly into the eye. The second retinal proliferative disease treatment can be, for example, an anti-VEGF agent (e.g., an anti-VEGF-A antibody or fragment thereof, such as bevacizumab (Avastin), ranibizumab (Levofloxacin), an anti-VEGF aptamer (e.g., pegaptanib (Magujin)), or another VEGF antagonist, such as aflibercept (Elia, a recombinant fusion protein consisting of a vascular endothelial growth factor (VEGF) binding portion from the extracellular domain of human VEGF receptors 1 and 2 fused to the Fc portion of a human IgG1 immunoglobulin), a steroid (e.g., a corticosteroid), an immunomodulatory therapy (IMT) drug (e.g., methotrexate, azathioprine, or mycophenolate mofetil), a biological response modifier (BRM) drug (anti-TNFα agent, such as an antibody or fragment thereof that binds TNFα, such as infliximab or adalimumab). Preferably, the second agent is an anti-VEGF agent. Preferably, the topically administered agent is a drug consisting of amino acids 19 to 168 of the amino acid sequence in Figure 2 (SEQ ID NO: 2), SEQ ID NO: 3, or SEQ ID NO: 4. NO:22, 23, 24, 25, preferably amino acids 19 to 168 of SEQ ID NO:2 or a protein consisting of SEQ ID NO:22.
[0484] Systemic administration
[0485] In other embodiments, the nomacopan-type protein or agent is administered systemically, such as subcutaneously.
[0486] Therapeutically or preventively effective amount
[0487] The agent is administered in a therapeutically or prophylactically effective amount. The term "therapeutically effective amount" refers to the amount of an agent required to treat the relevant condition, such as a retinal proliferative disease. In this context, "treating" includes lessening the severity of the condition.
[0488] As used herein, the term "prophylactically effective amount" refers to the amount of an agent required to prevent a condition of interest, such as a retinal proliferative disease. In this context, "prevention" includes reducing the severity of a condition, such as where the condition was not detected prior to the start of administration of the agent. Reducing the severity of a condition can, for example, improve visual acuity.
[0489] Relief or improvement is relative to the results without the administration of an agent as described herein. Results are assessed according to standard criteria for assessing the patient. In quantitative terms, there is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% relief or improvement in the relative criteria.
[0490] For systemic administration, the dosage calculated on the basis of the nomacopan molecule is 0.1 mg / kg / day to 10 mg / kg / day (mass of drug compared to patient mass), such as 0.2 to 5, 0.25 to 2, or 0.1 to 1 mg / kg / day. Because fusion proteins (e.g., as discussed herein) are larger than nomacopan molecules, equivalent molar amounts can be used for the proteins. Thus, for functional equivalents of nomacopan, equivalent molar amounts of the above dosages can be used. For example, for a fusion protein comprising nomacopan and a PAS portion of about 600 amino acids or a PAS portion as defined herein, such as PAS-nomacopan), the equivalent molar amount of 0.1 mg / kg / day is 0.4 mg / kg / day, and thus the dosage can be 0.4 mg / kg / day to 40 mg / kg / day (mass of drug compared to patient mass), such as 0.8-20, 1-8, or 0.4-4 mg / kg / day. Alternatively, and taking into account the longer half-life of these fusion proteins, larger amounts may be given per dose and the doses administered less frequently, for example 40 mg-2 g, 50 mg-1.5 g, 75 mg-1 g within a week, for example once or twice a week.
[0491] A therapeutically or prophylactically effective amount may be additionally defined with respect to inhibition of terminal complement, e.g., meaning an amount that reduces terminal complement activity by at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% compared to terminal complement activity (TCA) in the absence of treatment. Dosage and frequency may be adjusted to maintain terminal complement activity at a desired level, which may be, for example, 10% or less, e.g., 9, 8, 7, 6, 5, 4, 3, 2, 1% or less, compared to terminal complement activity in the absence of treatment.
[0492] A therapeutically or prophylactically effective amount may be further defined with respect to reducing LTB4 levels in plasma, for example, meaning an amount that reduces LTB4 levels in plasma by at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% compared to the LTB4 level in plasma in the absence of treatment, or an amount that brings LTB4 levels within a certain range of normal levels (e.g., 90% to 110% of normal levels, 85% to 115% of normal levels). Dosage and frequency can be adjusted to maintain the level of LTB4 in plasma at a desired level, which can be, for example, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% or less, such as 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less, or within a range of normal levels (e.g., 90% to 110% of normal levels, 85% to 115% of normal levels) compared to the level of LTB4 in plasma in the absence of treatment. LTB4 levels can be determined by conventional methods (e.g., immunoassays, see, for example, the commercially available R&D Systems assay based on sequential competitive binding technology
[58] ).
[0493] When dosages are given, this relates to dosages of agents that are proteins or functional equivalents thereof. Appropriate dosages of agents that are nucleic acid molecules can be used to produce these levels. Dosages can be varied to account for the presence of inactive proteins present (e.g., PAS-nomacopan with a 600 amino acid PAS portion has approximately 4× the molecular weight of nomacopan, so the equivalent molar amount will be approximately four times the amount of nomacopan). The equivalent molar amount of any dose of nomacopan provided can be used for any of its nomacopan functional equivalents containing additional sequences. The equivalent molar amount can be calculated using conventional methods.
[0494] Terminal complement activity can be measured by standard assays known in the art, such as using the Quidel CH 50 Hemolysis assay and sheep erythrocyte lysis CH50 assay.
[0495] The frequency with which the dosage needs to be administered will depend on the half-life of the agent involved. The nomacopan protein or a functional equivalent thereof can be administered, for example, twice daily, daily or every two, three, four, five, six or seven days or longer, such as twice daily or daily). Half-life extended forms, such as PAS-derived nomacopan molecules can be administered less frequently (e.g. every two, three, four, five, six, seven, 10, 15 or 20 days or longer, such as every day or every two days or longer, or once a week).
[0496] The exact dosage and dosage frequency may also depend on the patient's state at the time of administration. Factors that may be considered when determining dosage include the need for treatment or prevention, the severity of the patient's disease state, the patient's general health, age, weight, sex, diet, administration time and frequency, drug combination, reaction sensitivity, and the patient's tolerance or response to therapy. The exact amount may be determined by routine experimentation, but may ultimately depend on the judgment of the clinician.
[0497] The dosage regimen may also take the form of an initial "ablating regimen" followed by one or more subsequent doses (e.g., maintenance doses). Generally, the ablating regimen will be greater than the one or more subsequent doses. For example, for nomacopan, this may be 0.6 to 1.2 mg / kg, followed by an ablating regimen of 0.3 to 0.6 mg / kg after 8 to 18, 10 to 14, or 11 to 13 hours (e.g., about 12 hours), followed by a maintenance dose of 0.45 to 0.9 mg / kg, which may be administered, for example, once daily.
[0498] For PASylated forms (e.g., PAS-nomacopan, e.g., as described elsewhere herein, a suitable regimen may be 6 to 12 mg / kg (e.g., 600 mg), followed by a elimination regimen of 6 to 12 mg / kg (e.g., 600 mg) for 3 to 10, 4 to 8, 5 to 7 days, e.g., about 7 days later, followed by a maintenance dose of 4 to 8 mg / kg (e.g., 400 mg), which may be administered, e.g., once daily.
[0499] One or more elimination doses can be at least 1.5 times, 2 times or 5 times larger than the maintenance dose. The elimination dose can be used as a single dose, or one or more doses (e.g., two doses) in a specific time range. Typically, the initial dose will be 1, 2, 3, 4 or 5 doses administered in a single 24-hour period (or for a half-life extension form, a single week). The maintenance dose can be a lower dose repeated at regular time intervals. The maintenance dose can be repeated at certain intervals, such as every 12, 24 or 48 hours (or for a half-life extension form, weekly, or every two weeks). The exact scheme can be determined by routine experiments, but may ultimately depend on the judgment of the clinician. The maintenance dose can be at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the initial elimination dose, or at most 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the initial elimination dose.
[0500] In another embodiment, the same dose is used throughout the entire course of treatment (eg, daily or twice daily or weekly).
[0501] Preferably, the topical dose of nomacopan-type protein is between 50 and 500 μg per dose, more preferably between 100 and 400 μg per dose, and most preferably between 200 and 300 μg per dose. Alternatively, the dose may be 500 to 2000, 600 to 1500, 700 to 1250 or about 1250 μg per dose. For fusion proteins, the dose may be selected to give a comparable molar amount of the active agent, for example about 4 times the amount per dose for PAS-nomacopan (e.g., between 400 and 1600 μg per dose, and most preferably between 800 and 1200 μg per dose). Alternatively, the dose may be 2000 to 8000, 2400 to 6000, 2800 to 5000 or about 5000 μg per dose.
[0502] In topical compositions, instructions are usually given for a certain number of drops or length of ointment to be applied to the eye. It will be routine for one skilled in the art to adjust the concentration of the nomacopan-type protein in any composition to ensure that the correct dose is applied when the application instructions are followed. For example, one drop is typically about 40 μl, and thus a drop of a solution containing 0.5% w / v nomacopan or L-nomacopan will contain 200 μg nomacopan or L-nomacopan. Likewise, a drop of a solution containing 2% w / v PAS-nomacopan or PAS-L-nomacopan will contain 800 μg PAS-nomacopan or PAS-L-nomacopan. Because the molecular weight of PAS-nomacopan or PAS-L-nomacopan is approximately 4 times that of nomacopan or L-nomacopan, equal volumes of a solution containing 2% w / v PAS-nomacopan or PAS-L-nomacopan, a solution containing 0.5% w / v nomacopan or L-nomacopan provide equivalent molar amounts of the nomacopan portion of the protein. Similar doses of nomacopan-type molecules can be used for direct administration into the eye. When applying the composition directly into the eye, a volume of, for example, 10 to 50 μl can be used. It would be routine for one skilled in the art to adjust the concentration of the nomacopan-type protein in any composition to ensure that the correct dose is administered. For example, if 50 μl of a solution containing 0.5% w / v nomacopan or L-nomacopan is used, it would contain 250 μl of nomacopan or L-nomacopan. Likewise, one drop of a solution containing 2% w / v PAS-nomacopan or PAS-L-nomacopan would contain 1000 μg PAS-nomacopan or PAS-L-nomacopan.
[0503] Compositions for topical administration or direct administration into the eye may also be defined with respect to their nomacopan-type protein concentration, e.g. 0.1-20% w / v, 0.2-15, 0.25-10, 0.5-5% w / v (e.g. 0.4-80, 0.8-60, 1-40, 2-20% w / v for its PASylated form).
[0504] Pharmaceutical preparations
[0505] The agent will generally be administered in combination with or contained in a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" will generally be a liquid or may include other agents, provided that the carrier itself does not induce toxic effects or cause the production of antibodies harmful to the individual receiving the pharmaceutical composition. A pharmaceutically acceptable carrier may, for example, contain a liquid such as water, saline, glycerol, ethanol or an adjuvant substance such as a wetting agent or emulsifier, pH buffering substance, etc. The pharmaceutical carrier used will therefore vary depending on the route of administration. A full discussion of pharmaceutically acceptable carriers can be found in
[59] . In a preferred embodiment, the agent is administered in an ophthalmically acceptable composition, which may be a liquid, such as a solution in water or PBS.
[0506] The agent may optionally be delivered using a colloidal delivery system such as liposomes, nanoparticles or microparticles (e.g. as discussed in
[60] ). Advantages of these carrier systems include protection of sensitive proteins, prolonged release, reduced frequency of administration, patient compliance and controlled plasma levels.
[0507] Liposomes (e.g., comprising phospholipids of synthetic and / or natural origin) can be, for example, 20 nm 100 or 200 microns, such as small unilamellar vesicles (25-50 nm), large unilamellar vesicles (100-200 nm), giant unilamellar vesicles (1-2 μm), or multilamellar vesicles (MLV; 1 μm-2 μm).
[0508] Nanoparticles (colloidal carriers ranging in size from 10 to 1000 nm) can be made of lipids, polymers, or metals. Polymeric nanoparticles can be made of natural or synthetic polymers (e.g., chitosan, alginate, PCL, polylactic acid (PLA), poly(glycolide), PLGA) and can be produced as nanospheres (molecules are uniformly distributed into a polymer matrix) or nanocapsules (carrying drug molecules confined within a polymer membrane).
[0509] Microparticles made of, for example, starch, alginate, collagen, poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL) may also be used.
[0510] Alternatively or additionally a hydrogel may be present.
[0511] For larger molecular weight molecules, such as fusion proteins, additional excipients, such as hyaluronidase, may also be used, for example to allow administration of larger volumes (eg 2-20 ml).
[0512] Duration of treatment
[0513] Preferably, the course of treatment lasts for at least 1, 2, 3, 4, 5, or 6 weeks, or at least 1, 2, 3, 4, 5, or 6 months, or at least 1, 2, 3, 4, 5, or 6 years. The course of treatment preferably lasts at least until the subject's symptoms are alleviated. The course of treatment can therefore administer the agent (e.g., daily, every other day, or weekly) for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40 weeks.
[0514] BRIEF DESCRIPTION OF THE DRAWINGS
[0515] Figure 1A : Schematic representation of the classical and alternative pathways of complement activation. Anaphylatoxins are located in the starburst.
[0516] Figure 1B : Schematic representation of the eicosanoid pathway.
[0517] Figure 2A : Primary sequence of nomacopan. The signal sequence is underlined. Cysteine residues are in bold. Nucleotide and amino acid numbers are indicated on the right.
[0518] Figure 2B : Examples of nomacopan variants
[0519] Figure 2C : Examples of nomacopan variants that bind LTB4 but exhibit reduced or absent binding to C5.
[0520] Figure 2D and 2E : Exemplary PAS-nomacopan (D) and PAS-L-nomacopan sequences (E).
[0521] Figure 3 : Shows the results of fundus examination of individual eyes (n=12) 7 days after topical treatment on day 21 after immunization. Bars indicate SD or SEM, and a two-tailed nonparametric t-test has been applied.
[0522] Figure 4 : Showing BLT1 (LTB4 receptor) and C5a receptors on cells in the retina of mice used in the experimental autoimmune uveitis (EAU) model. The image shows infiltrating cells captured in the vitreous. The nuclei are shown in blue, BLT1 is shown in green and the C5a receptor is shown in red. There are cells expressing both receptors (yellow). Cells are indicated by arrows.
[0523] Figure 5: Clinical scores in EAU mice are shown before treatment on day 15 after immunization and after intravitreal administration of nomacopan-type proteins on day 18 after immunization. Funduscopy evaluation of disease was performed on individual eyes (n=16) on day 15 (before treatment) and day 22 (after treatment). EAU mice were treated intravitreally with 1-2 μl of the indicated compounds on days 15 and 18. Representative fundus and corresponding histopathological images are shown, along with a graphical summary showing the histological scores from treated mice (n=3 per group) (nomacopan bars indicate SD or SEM, and a two-tailed nonparametric t-test has been applied.
[0524] Figure 6: Shows the results of flow cytometric analysis of cells. (AB) RORgt / T.bet+ expression in CD4+ infiltrating cells in EAU mice (RORgt expression on the y-axis and Tbet expression on the x-axis). (CD) RORgt+ expression alone in CD4+ cells (RORgt expression on the x-axis, FSC-H on the y-axis). (EF) T.bet expression alone in CD4+ cells (T.bet expression on the x-axis, FSC-H on the y-axis). (GH) IL-17A expression in CD4+ cells (IL-17A expression on the x-axis, FSC-H on the y-axis). Figure 6b , Figure 6d , Figure 6f and Figure 6h In each of the , the top row of results on each page is for saline-treated EAU mice, the second row is for nomacopan-treated mice, the third row is for PAS-nomacopan-treated mice, the fourth row is for PAS-L-nomacopan-treated mice, and the fifth row is for dexamethasone-treated mice. Figures 6A, 6C, 6E, and 6G show a graphical summary of the corresponding expression levels. The bars indicate SEM. The figures show the average of 8 mice in each group (DEX n=6).
[0525] Fig. 7: (A) shows the VEGF levels in retinal tissue of the experimental autoimmune uveitis (EAU) mouse model using B10.RIII mice. Each group of mice was treated intravitreally with nomacopan (noma), PAS-nomacopan (PAS-noma), anti-VEGF antibody (anti-VEGF) or saline. Retinal tissue was collected 21 days after induction. Uninduced untreated healthy mice were used as negative control group ("healthy ct"). There were six mice in each intravitreal injection group and two uninduced untreated mice ("healthy ct"). ELISA analysis was used to analyze the VEGF levels of retinal tissue. All analyses were performed twice on duplicate samples. (B) Clinical scores in EAU mice are shown before treatment on day 15 after immunization and after intravitreal administration of nomacopan-type proteins on day 18 after immunization. Evaluation was performed on days 15 and 26. (C) Superimposed clinical scores are shown.
[0526] Example
[0527] Materials and Methods for Examples 1-3
[0528] EAU induction
[0529] EAU was induced as described previously
[61] by immunizing C57 / Bl6 mice (female, 5-7 weeks old, Charles River) subcutaneously with 300 μg of interphotoreceptor retinoid binding protein (IRBP) 161-180 peptide (SGIPYIISYLHPGNTILHVD, Cambridge Peptides, Cambridge, UK) in PBS emulsified with Mycobacterium tuberculosis (Difco, Voigt Global Distribution, Lawrence, KS). Mice also received 0.4 μg of pertussis (Sigma-Aldrich) intraperitoneally.
[0530] deal with
[0531] According to previous studies [62,], retinal inflammation was monitored for scoring starting from day 14 (mice were included in the study only if retinal inflammation was detected as assessed by retinal funduscopy starting on day 14). Mice were collected on days 1, 2, and 5 (n=6 per group).
[0532] For intravitreal administration, mice were treated with 1-2 μl nomacopan (5 mg / ml), PAS-nomacopan (20 mg / ml), PAS-L-nomacopan (20 mg / ml), dexamethasone or saline on days 15 and 18 after immunization. For topical administration, mice were treated twice daily with 2-5 μl nomacopan (5 mg / ml), PAS-nomacopan (20 mg / ml), L-nomacopan (5 mg / ml), dexamethasone (Maxidex; DEX) or saline for 7 days. Disease progression was clinically graded and histologically scored by funduscopy of the retina before and after treatment.
[0533] EAU score
[0534] Mice were regularly assessed for signs of EAU by regular fundus observations as described previously (eg, using a Micron III fundus camera (Phoenix Research Labs, Pleasanton, CA)). Clinical scoring was based on observations of the retinal optic disc, retinal vasculature, retinal tissue infiltration, and structural damage.
[0535] At the end of the experiment, one eye was collected from each mouse and fixed and embedded for histological scoring (e.g., enucleated and fixed in 4% glutaraldehyde for 1 hour and transferred to 10% formaldehyde for at least 24 hours, embedded, processed for H&E staining, and histologically examined). As previously described
[63] , scores were assigned on a scale of 0 to 5 based on the level of immune cell infiltration and the extent of retinal damage according to the EAU scoring criteria. Immunofluorescence staining for monocyte, neutrophil, and T cell infiltration can be performed to identify any changes in the infiltrating cell population.
[0536] For retinal flow cytometry, retinal layers were collected, minced, filtered and resuspended in culture medium for ex vivo stimulation (4 h) and stained for cell surface and intracellular markers 64
[0537] Example 1 EAU treatment using topical application of nomacopan-type proteins
[0538] like Figure 3As shown in, clinical scores in EAU mice were lower after topical administration of nomacopan (5 mg / ml), PAS-nomacopan (20 mg / ml), L-nomacopan (5 mg / ml) compared to mice treated with saline alone, with the results being statistically significant for L-nomacopan. A trend was observed for mice treated with nomacopan and PAS-nomacopan. The clinical scores of L-nomacopan-treated mice were consistent with those of dexamethasone-treated mice. Mean score ± SEM; 8.083 ± 0.848; n = 12) relative to the saline control group (10.33 ± 0.666; n = 12; P = 0.048), with no significant changes in CD4+ T cell numbers or subtypes in treated mice.
[0539] These results were unexpected as the test molecule was not previously known to cross the cornea.The reduced efficacy of PAS-nomacopan compared to the non-PASylated form may reflect the fact that the PASylated form is larger.
[0540] Example 2 Co-expression of BLT1 and C5a receptors in mouse retinal cells
[0541] Confocal microscopy of mouse retinal sections from UAE mice counterstained with DAPI (blue indicates cell nuclei) using monoclonal antibodies recognizing BLT1 and C5a receptors shows both receptors expressed in inflammatory cells. Some individual cells co-express both receptors, while many cells expressing a single receptor were also observed. It is believed that at least some of these cells are M2 macrophages, which are known to migrate to areas of retinal damage where they release VEGF in response to LTB4 stimulation (see Figure 4 , Figure 7 and Example 4).
[0542] This is consistent with other results presented herein that nomacopan-type proteins may be useful agents for treating such diseases (eg, diseases in which LTB4 is implicated and / or in which the complement pathway is implicated).
[0543] Example 3 EAU treatment using intravitreal administration of nomacopan-type proteins
[0544] like Figure 5As shown in, after intravitreal administration of nomacopan-type proteins on days 15 and 18 (nomacopan (5 mg / ml), PAS-nomacopan (20 mg / ml), PAS-L-nomacopan (20 mg / ml), each administered to EAU mice in a volume of 1-2 μl), the clinical scores observed on day 22 were generally lower than those in control (saline-treated) mice, and the increase in clinical scores between the two time points (days 15 and 22) in treated mice was smaller than that in control (saline-treated) mice. PAS-nomacopan alleviated disease progression after intravitreal administration as determined by clinical scores (mean score ± SEM; 3.813 ± 1.014; n = 16) relative to saline control groups (12.36 ± 1.014; n = 16; P = 0.0001).
[0545] Figure 5 The composite histology scores of the various treatments are also shown. Again, the clinical scores after treatment with each Nomocopan-type molecule were lower compared to the control (saline-treated) mice, and the difference between the composite histology scores of the control (saline-treated) mice and the composite histology scores of the PAS-L-nomacopan (20 mg / ml)-treated mice was statistically significant.
[0546] For example, and also Figure 5 As shown in , retinal folding (one of the components of the composite histology score) was visually very different in control (saline treated) mice compared to PAS-L-nomacopan (20 mg / ml) treated mice.
[0547] These data demonstrate for the first time that nomacopan-type proteins are biologically active when injected intravitreally (i.e., they have the ability to penetrate Bruch's membrane and / or the inner limiting membrane to act on cells present in the choroid). This is in contrast to other protein molecules that have been tested for ocular therapy, such as Lampalizumab
[65] .
[0548] RORgt / T.bet+ expression in CD4+ infiltrating cells in EAU mice was also analyzed by flow cytometry (see Figure 6a-b, which shows the percentage of RORgt / T.bet cells in CD4+ cells, where RORgt is expressed on the y-axis and Tbet is expressed on the x-axis). RORgt and Tbet are T cell markers associated with Th17 cell type and IL-17 expression. The percentage of RORgt / T.bet+ expressing cells in CD4+ infiltrating cells in EAU mice was lower in mice treated with nomacopan-type proteins compared to control (saline-treated) mice. The levels were lowest in mice treated with PAS-nomacopan (20 mg / ml), and the difference between the levels in these mice and control (saline-treated) mice was statistically significant. After two intravitreal treatments (days 15 and 18), retinal double-positive Th1 / Th17 (RORγt + T-bet + ) cells (4.717±2.627; n=8), while the expression levels of other T cell subsets showed no significant differences (data not shown).
[0549] RORgt+ expression alone and T.bet expression alone were also analyzed in these cells (see Figure 6c-6f ).
[0550] IL-17A expression was also analyzed in these cells (see Figure 6g-6h Th17 (IL-17A) expression in nomacopan and PAS-nomacopan treated groups (mean % ± SEM; 14.67 ± 3.534 and 7.019 ± 3.005, respectively, n = 8) was detected relative to saline control group (27.47 ± 3.461; n = 8; P = 0.02 and 0.0007). + CD4 + ) cell reduction.
[0551] Example 4 VEGF levels in EAU mice and treatment with intravitreal administration of nomacopan-type proteins
[0552] Materials and methods
[0553] EAU induction
[0554] EAU was induced by immunizing B10.RIII mice (female, 5-7 weeks old, self-bred colony) subcutaneously with 300 μg of inter-photoreceptor retinoid binding protein (IRBP) 161-180 peptide (SGIPYIISYLHPGNTILHVD). An appropriate protocol for EAU is described in
[61] , in which a solution of IRBP (Cambridge Peptides, Cambridge, UK) in PBS is emulsified with complete Freund's adjuvant (CFA, Sigma-Aldrich, Gillingham, UK) supplemented with Mycobacterium tuberculosis (Difco, Voigt Global Distribution, Lawrence, Kansas). In this protocol, mice also received 0.4 μg of Pertussis (Sigma-Aldrich) intraperitoneally.
[0555] Treatment and VEGF measurement
[0556] In initial experiments, retinal tissues were collected after induction to determine VEGF levels. Retinal tissues were analyzed for VEGF levels using an ELISA assay.
[0557] In subsequent experiments, retinal tissue was collected 21 days after induction. Each group of mice was treated intravitreally with 1-2 μl nomacopan (5 mg / ml), L-nomacopan (5 mg / ml), PAS-nomacopan (20 mg / ml), PAS-L-nomacopan (20 mg / ml), anti-VEGF antibody (50 μg / ml) BioLegend (Ultra-Leaf purified anti-mouse VEGF A antibody) or normal saline on the 15th and 18th day after induction. Uninduced untreated healthy mice were used as negative control group ("healthy ct"). There were six mice in each intravitreal injection group and there were two uninduced untreated healthy mice ("healthy ct"). The VEGF level of retinal tissue was analyzed using the ELISA analysis (mouse Quantikine ELISA) of mouse VEGF from R&D. All analyses were performed twice on duplicate samples.
[0558] result
[0559] The VEGF levels in the retinal tissues of these groups are shown in Fig. 7A In initial experiments, induction with IRBP resulted in a significant increase in VEGF levels compared to normal controls (data not shown). Fig. 7A It can also be seen in the increase when comparing "Saline" to "Healthy CT".
[0560] Fig. 7APAS-nomacopan was shown to be at least as effective as anti-VEGF antibodies in reducing retinal VEGF concentrations in this EAU model. Because nomacopan and its variants are not known to have any direct effects on VEGF, the reduction in VEGF levels is thought to be an indirect effect of inhibiting LTB4-based activation of M2 macrophages, which are assumed to be the major source of VEGF in this model
[35] .
[0561] Although L-nomacopan and PAS-L-nomacopan were also tested, the available results for L-nomacopan were inconclusive. The inconclusive results were considered to be the result of experimental error and are therefore not presented here.
[0562] It is believed that the clearance of LTB4 from neutrophils by nomacopan-type proteins also has the effect of reducing the retinal to peripheral blood LTB4 concentration gradient, thereby reducing inflammatory cell trafficking of Th-17 cells (as shown in Example 3) and macrophages and inhibiting their activation. The additional reduction of complement C5a and the membrane attack complex by nomacopan and PAS-nomacopan on the inhibitory effect of complement C5 can also further reduce the secondary release of VEGF by reducing the C5a concentration gradient and reducing the activation of inflammatory cells including Th cells, neutrophils and monocytes / macrophages. Reducing the trafficking of neutrophils can also reduce the amount of LTB4 available for release.
[0563] like Figure 7B and 7C Clinical scores were obtained as shown in .
[0564] Anti-VEGF antibodies had little or no effect on inflammation in this model, however inhibition of inflammation was observed with some of the molecules tested.
[0565] ---------------------------------
[0566] [1] Hoover et al., 1984, Proc. Nat. Acad. Sci. USA 81, 2191-2193
[0567] [2] Harrison and Murphy, 1995, J. Biol. Chem. 270, 17273-17276
[0568] [3]Ford-Hutchinson,1990,Crit.Rev.Immunol.10,1-12
[0569] [4] Showell et al., 1995, J. Pharm. Exp. Ther. 273, 176-184
[0570] [5] Klaas et al., 2005 J. Exp. Med. 201, 1281-1292
[0571] [6] Del Prete et al., 2007 Blood, 109, 626-631.
[0572] [7] Miyahara et al., 2006 Allergol Int. 55, 91-7
[0573] [8] Taube et al., 2006 J. Immunol. 176, 3157-3164
[0574] [9] Yamaoka et al., 1989 J. Immunol. 143, 1996-2000
[0575]
[10] Yokomizo et al., 1997 Nature 387, 620-624
[0576]
[11] Yokomizo et al., 2000 J. Exp. Med. 192, 421-432
[0577]
[12] Tager and Luster,2003Prostaglandins Leukot.Essent.Fatty Acids 69,123-134
[0578]
[13] Yokomizo et al., 2001, J. Biol. Chem. 276, 12454-12459
[0579]
[14] Kim, ND and Luster, AD (2007) The Scientific World Journal 7, 1307-1328.
[0580]
[15] Kim et al., 2006. J. Exp. Med. 203, 829-835
[0581]
[16] Noiri et al., 2000 Proc Nat Acad Sci USA 97, 823-828
[0582]
[17] Lundeen et al., 2006. J. Immunol. 177, 3439-3447.
[0583]
[18] Shao et al., 2006. J. Immunol. 176, 6254-6261
[0584]
[19] Chen et al., 2006. J. Exp. Med. 203, 837-842
[0585]
[20] Sebaldt et al., 1990 Proc Natl Acad Sd. USA 8, 6974-6978
[0586]
[21] Curry et al., 2005Journal of the American Animal Hospital Association41,298-309
[0587]
[22] Dube et al., 1998. Zileuton: the first leukotriene inhibitor for use in the management of chronic asthma. In: Drazen JM, Dahlen S, Lee TH, eds. Five-lipoxygenase Products in Asthma. New York, NY: Marcel Dekkar, Inc.
[0588]
[23] Sharma and Mohammed,2006Immunopharmacology 14,10-16
[0589]
[24] WO2004 / 106369
[0590]
[25] Jore, MM et al., Nature Structural & Molecular Biology 2016, Vol. 23, pp. 378–386
[0591]
[26] Xu et al. European Journal of Pharmacology 2016 787 94
[0592]
[27] Anaya JM et al. Autoimmunity: From Bench to Bedside, Chapter 37-Autoimmune uveitis, Bogota (Colombia): El Rosario University Press; July 18, 2013.
[0593]
[28] Guedes et al., Indian J Ophthalmol. 2016;64(9):628–634
[0594]
[29] Gulati et al. Br J Ophthalmol 2011 95:162-165
[0595]
[30] Mitchell and Bradley, Health Qual Life Outcomes. 2006; 4:97.
[0596]
[31] Delcourt et al Investigative Ophthalmology&Visual Science 2017,58,6399-6407
[0597]
[32] Clinical Classification of Age-related Macular Degeneration, Ophthalmology 2013;120:844–851.
[0598]
[33] Xu and Chen Eur J Pharmacol. 2016 15;787:94–104.
[0599]
[34] Ferrara et al. Annu.Rev.Med.2007.58:491–504
[0600]
[35] Sasaki et al. JCI Insight. 2018 Sep 20; 3(18). pii:96902.
[0601]
[36] Cai&McGinnis,J Diabetes Res.2016;2016:3789217
[0602]
[37] Borke et al. Medscape 2017, Retinal Vein Occlusion (RVO)
[0603]
[38] The Royal College of Ophthalmologists, Clinical Guidelines Retinal Vein Occlusion (RVO) Guidelines 2017
[0604]
[39] An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity. Arch Ophthalmol. 1984; 102(8): 1130-4.
[0605]
[40] Sankar et al. Cochrane Database of Systematic Reviews 2018, Issue 1. Number: CD009734.
[0606]
[41] Lu et al. Graefes Arch Clin Exp Ophthalmol, 2017, 255: 1057–1062
[0607]
[42] Battaglia et al. Br J Ophthalmol, 2015, 99: 1268–1270
[0608]
[43] https: / / eyewiki.aao.org / Polypoidal_Choroidal_Vasculopathy#cite_ref-Yannuzzi_1_1-0
[0609]
[44] Roversi, P et al. Journal of Biological Chemistry 2013, 288(26)18789-18802
[0610]
[45] Guo, RF and PA Ward, Annu Rev Immunol, 2005, 23: p.821-52
[0611]
[46] Ricklin D&Lambris J, Nature Biotechnology, 25:1265-1275(2007)
[0612]
[47] Nishimura, J et al., New Engl J. Med., 30;7:632-639 (2014)
[0613]
[48] Breustedt DA, DL, Skerra A. (2006) Comparative ligand-binding analysis of ten human lipocalins. Biochim Biophys Acta 1764(2):161-173.
[0614]
[49] Roversi et al. (2013) J Biol Chem. 288, 18789-18802
[0615]
[50] Giclas 1994 (Giclas, PC (1994). Classical and alternative pathway evaluation (sections 13.1 and 13.2)). In Current Protocols in Immunology, vol. 3
[0616]
[51] Terpe K,Appl Microbiol Biotechnol,60:523-33,2003
[0617]
[52] Schlapschy M, et al. Protein Eng Des Sel. 2013Aug; 26(8): 489-501
[0618]
[53] Kuhn et al. Bioconjugate Chem., 2016, 27(10), pp 2359–2371
[0619]
[54] Sambrook et al. (2000)
[0620]
[55] Fernandez & Hoeffler (1998)
[0621]
[56] Ausubel et al. (1991)
[0622]
[57] Chiang B et al. Adv Drug Deliv Rev. 2018 Feb 15;126:58–66.
[0623]
[58] https: / / resources.rndsystems.com / pdfs / datasheets / kge006b.pdf
[0624]
[59] Remington's Pharmaceutical Sciences; Mack Pub. Co., NJ 1991
[0625]
[60] Patel et al. Ther. Deliv. (2014) 5(3), 337–365
[0626]
[61] Gardner et al. The American Journal of Pathology 2015, Vol. 185(5), 1324-1333.
[0627]
[62] Hertweck et al. 2016 Cell reports 15 2756
[0628]
[63] Gegg et al. 2005 J Immunol 174 2327-2335
[0629]
[64] Eskandarpour et al. 2017The Journal of Immunology 198:1093–1103
[0630]
[65] Holz et al. JAMA Ophthalmology June 2018, Vol. 136, No. 6 Sequence Listing <110> Volushin Imino Pharmaceuticals <120> Treatment <130> P077662WO <141> 2020-03-04 <160> 32 <170> SeqWin2010 Version 1.0 <210> 1 <211> 507 <212> DNA <213> Ornithodoros moubata <400> 1 atgctggttt tggtgaccct gattttctcc ttttctgcga acatcgcata tgctgacagc 60 gaaagcgact gcactggaag cgaacctgtt gacgccttcc aagctttcag tgagggcaaa 120 gaggcatatg tcctggtgag gtccacggat cccaaagcga gggactgctt gaaaggagaa 180 ccagccggag aaaagcagga caacacgttg ccggtgatga tgacgtttaa gaatggcaca 240 gactgggctt caaccgattg gacgtttact ttggacggcg caaaggtaac ggcaaccctt 300 ggtaacctaa cccaaaatag ggaagtggtc tacgactcgc aaagtcatca ctgccacgtt 360 gacaaggtcg agaaggaagt tccagattat gagatgtgga tgctcgatgc gggagggctt 420 gaagtggaag tcgagtgctg ccgtcaaaag cttgaagagt tggcgtctgg caggaaccaa 480 atgtatcccc atctcaagga ctgctag 507 <210> 2 <211> 168 <212> PRT <213> Ornithodoros moubata <400> 2 Met Leu Val Leu Val Thr Leu Ile Phe Ser Phe Ser Ala Asn Ile Ala 1 5 10 15 Tyr Ala Asp Ser Glu Ser Asp Cys Thr Gly Ser Glu Pro Val Asp Ala 20 25 30 Phe Gln Ala Phe Ser Glu Gly Lys Glu Ala Tyr Val Leu Val Arg Ser 35 40 45 Thr Asp Pro Lys Ala Arg Asp Cys Leu Lys Gly Glu Pro Ala Gly Glu 50 55 60 Lys Gln Asp Asn Thr Leu Pro Val Met Met Thr Phe Lys Asn Gly Thr 65 70 75 80 Asp Trp Ala Ser Thr Asp Trp Thr Phe Thr Leu Asp Gly Ala Lys Val 85 90 95 Thr Ala Thr Leu Gly Asn Leu Thr Gln Asn Arg Glu Val Val Tyr Asp 100 105 110 Ser Gln Ser His His Cys His Val Asp Lys Val Glu Lys Glu Val Pro 115 120 125 Asp Tyr Glu Met Trp Met Leu Asp Ala Gly Gly Leu Glu Val Glu Val 130 135 140 Glu Cys Cys Arg Gln Lys Leu Glu Glu Leu Ala Ser Gly Arg Asn Gln 145 150 155 160 Met Tyr Pro His Leu Lys Asp Cys 165 <210> 3 <211> 453 <212> DNA <213> Ornithodoros moubata <400> 3 gacagcgaaa gcgactgcac tggaagcgaa cctgttgacg ccttccaagc tttcagtgag 60 ggcaaagagg catatgtcct ggtgaggtcc acggatccca aagcgaggga ctgcttgaaa 120 ggagaaccag ccggagaaaa gcaggacaac acgttgccgg tgatgatgac gtttaagaat 180 ggcacagact gggcttcaac cgattggacg tttactttgg acggcgcaaa ggtaacggca 240 acccttggta acctaaccca aaatagggaa gtggtctacg actcgcaaag tcatcactgc 300 cacgttgaca aggtcgagaa ggaagttcca gattatgaga tgtggatgct cgatgcggga 360 gggcttgaag tggaagtcga gtgctgccgt caaaagcttg aagagttggc gtctggcagg 420 aaccaaatgt atccccatct caaggactgc tag 453 <210> 4 <211> 150 <212> PRT <213> Ornithodoros moubata <400> 4 Asp Ser Glu Ser Asp Cys Thr Gly Ser Glu Pro Val Asp Ala Phe Gln 1 5 10 15 Ala Phe Ser Glu Gly Lys Glu Ala Tyr Val Leu Val Arg Ser Thr Asp 20 25 30 Pro Lys Ala Arg Asp Cys Leu Lys Gly Glu Pro Ala Gly Glu Lys Gln 35 40 45 Asp Asn Thr Leu Pro Val Met Met Thr Phe Lys Asn Gly Thr Asp Trp 50 55 60 Ala Ser Thr Asp Trp Thr Phe Thr Leu Asp Gly Ala Lys Val Thr Ala 65 70 75 80 Thr Leu Gly Asn Leu Thr Gln Asn Arg Glu Val Val Tyr Asp Ser Gln 85 90 95 Ser His His Cys His Val Asp Lys Val Glu Lys Glu Val Pro Asp Tyr 100 105 110 Glu Met Trp Met Leu Asp Ala Gly Gly Leu Glu Val Glu Val Glu Cys 115 120 125 Cys Arg Gln Lys Leu Glu Glu Leu Ala Ser Gly Arg Asn Gln Met Tyr 130 135 140 Pro His Leu Lys Asp Cys 145 150 <210> 5 <211> 450 <212> DNA <213> Ornithodoros moubata <400> 5 agcgaaagcg actgcactgg aagcgaacct gttgacgcct tccaagcttt cagtgagggc 60 aaagaggcat atgtcctggt gaggtccacg gatcccaaag cgagggactg cttgaaagga 120 gaaccagccg gagaaaagca ggacaacacg ttgccggtga tgatgacgtt taagaatggc 180 gaaccagccg gagaaaagca ggacaacacg ttgccggtga tgatgacgtt taagaatggc 180 acagactggg cttcaaccga ttggacgttt actttggacg gcgcaaaggt aacggcaacc 240 acagactggg cttcaaccga ttggacgttt actttggacg gcgcaaaggt aacggcaacc 240 cttggtaacc taacccaaaa tagggaagtg gtctacgact cgcaaagtca tcactgccac 300 cttggtaacc taacccaaaa tagggaagtg gtctacgact cgcaaagtca tcactgccac 300 gttgacaagg tcgagaagga agttccagat tatgagatgt ggatgctcga tgcgggaggg 360 gttgacaagg tcgagaagga agttccagat tatgagatgt ggatgctcga tgcgggaggg 360 cttgaagtgg aagtcgagtg ctgccgtcaa aagcttgaag agttggcgtc tggcaggaac 420 cttgaagtgg aagtcgagtg ctgccgtcaa aagcttgaag agttggcgtc tggcaggaac 420 caaatgtatc cccatctcaa ggactgctag 450 caaatgtatc cccatctcaa ggactgctag 450 <210> 6<210> 6 <211> 149<211> 149 <212> PRT<212> PRT <213> 毛白钝缘蜱(Ornithodoros moubata)<213> Ornithodoros moubata <400> 6<400> 6 Ser Glu Ser Asp Cys Thr Gly Ser Glu Pro Val Asp Ala Phe Gln Ala Ser Glu Ser Asp Cys Thr Gly Ser Glu Pro Val Asp Ala Phe Gln Ala 1 5 10 15 1 5 10 15 Phe Ser Glu Gly Lys Glu Ala Tyr Val Leu Val Arg Ser Thr Asp Pro Phe Ser Glu Gly Lys Glu Ala Tyr Val Leu Val Arg Ser Thr Asp Pro 20 25 30 20 25 30 Lys Ala Arg Asp Cys Leu Lys Gly Glu Pro Ala Gly Glu Lys Gln Asp Lys Ala Arg Asp Cys Leu Lys Gly Glu Pro Ala Gly Glu Lys Gln Asp 35 40 45 35 40 45 Asn Thr Leu Pro Val Met Met Thr Phe Lys Asn Gly Thr Asp Trp Ala Asn Thr Leu Pro Val Met Met Thr Phe Lys Asn Gly Thr Asp Trp Ala 50 55 60 50 55 60 Ser Thr Asp Trp Thr Phe Thr Leu Asp Gly Ala Lys Val Thr Ala Thr 65 70 75 80 Leu Gly Asn Leu Thr Gln Asn Arg Glu Val Val Tyr Asp Ser Gln Ser 85 90 95 His His Cys His Val Asp Lys Val Glu Lys Glu Val Pro Asp Tyr Glu 100 105 110 Met Trp Met Leu Asp Ala Gly Gly Leu Glu Val Glu Val Glu Cys Cys 115 120 125 Arg Gln Lys Leu Glu Glu Leu Ala Ser Gly Arg Asn Gln Met Tyr Pro 130 135 140 His Leo Lys Asp Cys 145 <210> 7 <211> 447 <212> DNA <213> Ornithodoros moubata <400> 7 gaaagcgact gcactggaag cgaacctgtt gacgccttcc aagctttcag tgagggcaaa 60 gaggcatatg tcctggtgag gtccacggat cccaagcga gggactgctt gaaggagaa 120 ccagccggag aaagcagga cacacgttg ccggtgatga tgacgtttaa gatggcaca 180 gactgggctt caacgattg gacgtttact ttggacggcg caaggtaac ggcaaccctt 240 ggtaacctaa cccaaaatag ggaagtggtc tacgactcgc aaagtcatca ctgccacgtt 300 gacaaggtcg agaaggaagt tccagattat gagatgtgga tgctcgatgc gggagggctt 360 gaagtggaag tcgagtgctg ccgtcaaaag cttgaagagt tggcgtctgg caggaaccaa 420 atgtatcccc atctcaagga ctgctag 447 <210> 8 <211> 148 <212> PRT <213> Ornithodoros moubata <400> 8 Glu Ser Asp Cys Thr Gly Ser Glu Pro Val Asp Ala Phe Gln Ala Phe 1 5 10 15 Ser Glu Gly Lys Glu Ala Tyr Val Leu Val Arg Ser Thr Asp Pro Lys 20 25 30 Ala Arg Asp Cys Leu Lys Gly Glu Pro Ala Gly Glu Lys Gln Asp Asn 35 40 45 Thr Leu Pro Val Met Met Thr Phe Lys Asn Gly Thr Asp Trp Ala Ser 50 55 60 Thr Asp Trp Thr Phe Thr Leu Asp Gly Ala Lys Val Thr Ala Thr Leu 65 70 75 80 Gly Asn Leu Thr Gln Asn Arg Glu Val Val Tyr Asp Ser Gln Ser His 85 90 95 His Cys His Val Asp Lys Val Glu Lys Glu Val Pro Asp Tyr Glu Met 100 105 110 Trp Met Leu Asp Ala Gly Gly Leu Glu Val Glu Val Glu Cys Cys Arg 115 120 125 Gln Lys Leu Glu Glu Leu Ala Ser Gly Arg Asn Gln Met Tyr Pro His 130 135 140 Leu Lys Asp Cys 145 <210> 9 <211> 444 <212> DNA <213> Ornithodoros moubata <400> 9 agcgactgca ctggaagcga acctgttgac gccttccaag ctttcagtga gggcaaagag 60 gcatatgtcc tggtgaggtc cacggatccc aaagcgaggg actgcttgaa aggagaacca 120 gccggagaaa agcaggacaa cacgttgccg gtgatgatga cgtttaagaa tggcacagac 180 tgggcttcaa ccgattggac gtttactttg gacggcgcaa aggtaacggc aacccttggt 240 aacctaaccc aaaataggga agtggtctac gactcgcaaa gtcatcactg ccacgttgac 300 aaggtcgaga aggaagttcc agattatgag atgtggatgc tcgatgcggg agggcttgaa 360 gtggaagtcg agtgctgccg tcaaaagctt gaagagttgg cgtctggcag gaaccaaatg 420 tatccccatc tcaaggactg ctag 444 <210> 10 <211> 147 <212> PRT <213> Ornithodoros moubata <400> 10 Ser Asp Cys Thr Gly Ser Glu Pro Val Asp Ala Phe Gln Ala Phe Ser 1 5 10 15 Glu Gly Lys Glu Ala Tyr Val Leu Val Arg Ser Thr Asp Pro Lys Ala 20 25 30 Arg Asp Cys Leu Lys Gly Glu Pro Ala Gly Glu Lys Gln Asp Asn Thr 35 40 45 Leu Pro Val Met Met Thr Phe Lys Asn Gly Thr Asp Trp Ala Ser Thr 50 55 60 Asp Trp Thr Phe Thr Leu Asp Gly Ala Lys Val Thr Ala Thr Leu Gly 65 70 75 80 Asn Leu Thr Gln Asn Arg Glu Val Val Tyr Asp Ser Gln Ser His His 85 90 95 Cys His Val Asp Lys Val Glu Lys Glu Val Pro Asp Tyr Glu Met Trp 100 105 110 Met Leu Asp Ala Gly Gly Leu Glu Val Glu Val Glu Cys Cys Arg Gln 115 120 125 Lys Leu Glu Glu Leu Ala Ser Gly Arg Asn Gln Met Tyr Pro His Leu 130 135 140 Lys Asp Cys 145 <210> 11 <211> 441 <212> DNA <213> Ornithodoros moubata <400> 11 gactgcactg gaagcgaacc tgttgacgcc ttccaagctt tcagtgaggg caaagaggca 60 tatgtcctgg tgaggtccac ggatcccaaa gcgagggact gcttgaaagg agaaccagcc 120 ggagaaaagc aggacaacac gttgccggtg atgatgacgt ttaagaatgg cacagactgg 180 gcttcaaccg attggacgtt tactttggac ggcgcaaagg taacggcaac ccttggtaac 240 ctaacccaaa atagggaagt ggtctacgac tcgcaaagtc atcactgcca cgttgacaag 300 gtcgagaagg aagttccaga ttatgagatg tggatgctcg atgcgggagg gcttgaagtg 360 gaagtcgagt gctgccgtca aaagcttgaa gagttggcgt ctggcaggaa ccaaatgtat 420 ccccatctca aggactgcta g 441 <210> 12 <211> 146 <212> PRT <213> Ornithodoros moubata <400> 12 Asp Cys Thr Gly Ser Glu Pro Val Asp Ala Phe Gln Ala Phe Ser Glu 1 5 10 15 Gly Lys Glu Ala Tyr Val Leu Val Arg Ser Thr Asp Pro Lys Ala Arg 20 25 30 Asp Cys Leu Lys Gly Glu Pro Ala Gly Glu Lys Gln Asp Asn Thr Leu 35 40 45 Pro Val Met Met Thr Phe Lys Asn Gly Thr Asp Trp Ala Ser Thr Asp 50 55 60 Trp Thr Phe Thr Leu Asp Gly Ala Lys Val Thr Ala Thr Leu Gly Asn 65 70 75 80 Leu Thr Gln Asn Arg Glu Val Val Tyr Asp Ser Gln Ser His His Cys 85 90 95 His Val Asp Lys Val Glu Lys Glu Val Pro Asp Tyr Glu Met Trp Met 100 105 110 Leu Asp Ala Gly Gly Leu Glu Val Glu Val Glu Cys Cys Arg Gln Lys 115 120 125 Leu Glu Glu Leu Ala Ser Gly Arg Asn Gln Met Tyr Pro His Leu Lys 130 135 140 Asp Cys 145 <210> 13 <211> 438 <212> DNA <213> Ornithodoros moubata <400> 13 tgcactggaa gcgaacctgt tgacgccttc caagctttca gtgagggcaa agaggcatat 60 gtcctggtga ggtccacgga tcccaaagcg agggactgct tgaaaggaga accagccgga 120 gaaaagcagg acaacacgtt gccggtgatg atgacgttta agaatggcac agactgggct 180 tcaaccgatt ggacgtttac tttggacggc gcaaaggtaa cggcaaccct tggtaaccta 240 acccaaaata gggaagtggt ctacgactcg caaagtcatc actgccacgt tgacaaggtc 300 gagaaggaag ttccagatta tgagatgtgg atgctcgatg cgggagggct tgaagtggaa 360 gtcgagtgct gccgtcaaaa gcttgaagag ttggcgtctg gcaggaacca aatgtatccc 420 catctcaagg actgctag 438 <210> 14 <211> 145 <212> PRT <213> Ornithodoros moubata <400> 14 Cys Thr Gly Ser Glu Pro Val Asp Ala Phe Gln Ala Phe Ser Glu Gly 1 5 10 15 Lys Glu Ala Tyr Val Leu Val Arg Ser Thr Asp Pro Lys Ala Arg Asp 20 25 30 Cys Leu Lys Gly Glu Pro Ala Gly Glu Lys Gln Asp Asn Thr Leu Pro 35 40 45 Val Met Met Thr Phe Lys Asn Gly Thr Asp Trp Ala Ser Thr Asp Trp 50 55 60 Thr Phe Thr Leu Asp Gly Ala Lys Val Thr Ala Thr Leu Gly Asn Leu 65 70 75 80 Thr Gln Asn Arg Glu Val Val Tyr Asp Ser Gln Ser His His Cys His 85 90 95 Val Asp Lys Val Glu Lys Glu Val Pro Asp Tyr Glu Met Trp Met Leu 100 105 110 Asp Ala Gly Gly Leu Glu Val Glu Val Glu Cys Cys Arg Gln Lys Leu 115 120 125 Glu Glu Leu Ala Ser Gly Arg Asn Gln Met Tyr Pro His Leu Lys Asp 130 135 140 Cys 145 <210> 15 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> PAS Sequence <400> 15 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 1 5 10 15 Ser Ala Pro Ala 20 <210> 16 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> PAS Sequence <400> 16 Ala Ala Pro Ala Ser Pro Ala Pro Ala Ala Pro Ser Ala Pro Ala Pro 1 5 10 15 Ala Ala Pro Ser 20 <210> 17 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> PAS Sequence <400> 17 Ala Pro Ser Ser Pro Ser Pro Ser Ala Pro Ser Ser Pro Ser Pro Ala 1 5 10 15 Ser Pro Ser Ser 20 <210> 18 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> PAS Sequence <400> 18 Ser Ala Pro Ser Ser Pro Ser Pro Ser Ala Pro Ser Ser Pro Ser Pro 1 5 10 15 Ala Ser Pro Ser 20 <210> 19 <211> 20 <212> PRT <213> Artificial sequence <220> <223> PAS sequence <400> 19 Ser Ser Pro Ser Ala Pro Ser Pro Ser Ser Pro Ala Ser Pro Ser Pro 1 5 10 15 Ser Ser Pro Ala 20 <210> 20 <211> 24 <212> PRT <213> Artificial sequence <220> <223> PAS sequence <400> 20 Ala Ala Ser Pro Ala Ala Pro Ser Ala Pro Pro Ala Ala Ala Ser Pro 1 5 10 15 Ala Ala Pro Ser Ala Pro Pro Ala 20 <210> 21 <211> 20 <212> PRT <213> Artificial sequence <220> <223> PAS sequence <400> 21 Ala Ser Ala Ala Ala Pro Ala Ala Ala Ser Ala Ala Ala Ser Ala Pro 1 5 10 15 Ser Ala Ala Ala 20 <210> 22 <211> 150 <212> PRT <213> Artificial sequence <220> <223> Nomacopan Variant 1 <400> 22 Asp Ser Glu Ser Asp Cys Thr Gly Ser Glu Pro Val Asp Ala Phe Gln 1 5 10 15 Ala Phe Ser Glu Gly Lys Glu Ala Tyr Val Leu Val Arg Ser Thr Asp 20 25 30 Pro Lys Ala Arg Asp Cys Leu Lys Gly Glu Pro Ala Gly Glu Lys Gln 35 40 45 Asp Asn Thr Leu Pro Val Met Met Thr Phe Lys Asn Gly Thr Asp Trp 50 55 60 Ala Ser Thr Asp Trp Thr Phe Thr Leu Asp Gly Ala Lys Val Thr Ala 65 70 75 80 Thr Leu Gly Asn Leu Thr Gln Asn Arg Glu Val Val Tyr Asp Ser Gln 85 90 95 Ser His His Cys His Val Asp Lys Val Glu Lys Glu Val Pro Asp Tyr 100 105 110 Glu Gln Trp Gln Ser Asn Gly Ser Ala Asp Asp Lys Glu Val Glu Cys 115 120 125 Cys Arg Gln Lys Leu Glu Glu Leu Ala Ser Gly Arg Asn Gln Met Tyr 130 135 140 Pro His Leu Lys Asp Cys 145 150 <210> 23 <211> 150 <212> PRT <213> Artificial sequence <220> <223> Nomacopan variant 2 <400> 23 Asp Ser Glu Ser Asp Cys Thr Gly Ser Glu Pro Val Asp Ala Phe Gln 1 5 10 15 Ala Phe Ser Glu Gly Lys Glu Ala Tyr Val Leu Val Arg Ser Thr Asp 20 25 30 Pro Lys Ala Arg Asp Cys Leu Lys Gly Glu Pro Asn Gly Glu Lys Gln 35 40 45 Asp Asn Thr Leu Pro Val Met Met Thr Phe Lys Asn Gly Thr Asp Trp 50 55 60 Ala Ser Thr Asp Trp Thr Phe Thr Leu Asp Gly Ala Lys Val Thr Ala 65 70 75 80 Thr Leu Gly Asn Leu Thr Gln Asn Arg Glu Val Val Tyr Asp Ser Gln 85 90 95 Ser His His Cys His Val Asp Lys Val Glu Lys Glu Val Pro Asp Tyr 100 105 110 Glu Met Trp Gln Ser Asp Ala Gly Ala Asp Ala Val Glu Val Glu Cys 115 120 125 Cys Arg Gln Lys Leu Glu Glu Leu Ala Ser Gly Arg Asn Gln Met Tyr 130 135 140 Pro His Leu Lys Gly Cys 145 150 <210> 24 <211> 150 <212> PRT <213> Artificial Sequence <220> <223> nomacopan Variant 3 <400> 24 Asp Ser Glu Ser Asp Cys Thr Gly Ser Glu Pro Val Asp Ala Phe Gln 1 5 10 15 Ala Phe Ser Glu Gly Lys Glu Ala Tyr Val Leu Val Arg Ser Thr Asp 20 25 30 Pro Lys Ala Arg Asp Cys Leu Lys Gly Glu Pro Asn Gly Glu Lys Gln 35 40 45 Asp Asn Thr Leu Pro Val Met Met Thr Phe Lys Asn Gly Thr Asp Trp 50 55 60 Ala Ser Thr Asp Trp Thr Phe Thr Leu Asp Gly Ala Lys Val Thr Ala 65 70 75 80 Thr Leu Gly Asn Leu Thr Gln Asn Arg Glu Val Val Tyr Asp Ser Gln 85 90 95 Ser His His Cys His Val Asp Lys Val Glu Lys Glu Val Pro Asp Tyr 100 105 110 Glu Met Trp Gln Leu Asp Ala Gly Gly Asp Glu Val Glu Val Glu Cys 115 120 125 Cys Arg Gln Lys Leu Glu Glu Leu Ala Ser Gly Arg Asn Gln Met Tyr 130 135 140 Pro His Leu Lys Gly Cys 145 150 <210> 25 <211> 150 <212> PRT <213> Artificial Sequence <220> <223> nomacopan Variant 4 <400> 25 Asp Ser Glu Ser Asp Cys Thr Gly Ser Glu Pro Val Asp Ala Phe Gln 1 5 10 15 Ala Phe Ser Glu Gly Lys Glu Ala Tyr Val Leu Val Arg Ser Thr Asp 20 25 30 Pro Lys Ala Arg Asp Cys Leu Lys Gly Glu Pro Asn Gly Glu Lys Gln 35 40 45 Asp Asn Thr Leu Pro Val Met Met Thr Phe Lys Asn Gly Thr Asp Trp 50 55 60 Ala Ser Thr Asp Trp Thr Phe Thr Leu Asp Gly Ala Lys Val Thr Ala 65 70 75 80 Thr Leu Gly Asn Leu Thr Gln Asn Arg Glu Val Val Tyr Asp Ser Gln 85 90 95 Ser His His Cys His Val Asp Lys Val Glu Lys Glu Val Pro Asp Tyr 100 105 110 Glu Met Trp Met Leu Asp Ala Gly Gly Leu Glu Val Glu Val Glu Cys 115 120 125 Cys Arg Gln Lys Leu Glu Glu Leu Ala Ser Gly Arg Asn Gln Met Tyr 130 135 140 Pro His Leu Lys Asp Cys 145 150 <210> 26 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Ring sequence <400> 26 Met Trp Met Leu Asp Ala Gly Gly Leu Glu Val 1 5 10 <210> 27 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Loop sequence of nomacopan variant 1 <400> 27 Gln Trp Gln Ser Asn Gly Ser Ala Asp Asp Lys 1 5 10 <210> 28 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Loop sequence of nomacopan variant 2 <400> 28 Met Trp Gln Ser Asp Ala Gly Ala Asp Ala Val 1 5 10 <210> 29 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Loop sequence of nomacopan variant 3 <400> 29 Met Trp Gln Leu Asp Ala Gly Gly Asp Glu Val 1 5 10 <210> 30 <211> 751 <212> PRT <213> Artificial sequence <220> <223> PAS-nomacopan <400> 30 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 1 5 10 15 Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala 20 25 30 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 35 40 45 Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala 50 55 60 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 65 70 75 80 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 85 90 95 Ala Pro Ala Ala Cheese Ala Pro Ala Cheese Ala Pro Ala Pro Ala Cheese 100 105 110 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 115 120 125 Ala Cheese Pro Ala Ala Pro Ala Pro Ala Cheese Pro Ala Ala Cheese Pro Ala 130 135 140 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 145 150 155 160 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 165 170 175 Ala Pro Ala Ala Cheese Ala Pro Ala Cheese Ala Pro Ala Pro Ala Cheese 180 185 190 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 195 200 205 Ala Cheese Pro Ala Ala Pro Ala Pro Ala Cheese Pro Ala Ala Cheese Pro Ala 210 215 220 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 225 230 235 240 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 245 250 255 Ala Pro Ala Ala Cheese Ala Pro Ala Cheese Ala Pro Ala Pro Ala Cheese 260 265 270 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 275 280 285 Ala Cheese Pro Ala Ala Pro Ala Pro Ala Cheese Pro Ala Ala Cheese Pro Ala 290 295 300 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 305 310 315 320 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 325 330 335 Ala Pro Ala Ala Cheese Ala Pro Ala Cheese Ala Pro Ala Pro Ala Cheese 340 345 350 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 355 360 365 Ala Cheese Pro Ala Ala Pro Ala Pro Ala Cheese Pro Ala Ala Cheese Pro Ala 370 375 380 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 385 390 395 400 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 405 410 415 Ala Pro Ala Ala Cheese Ala Pro Ala Cheese Ala Pro Ala Pro Ala Cheese 420 425 430 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 435 440 445 Ala Cheese Pro Ala Ala Pro Ala Pro Ala Cheese Pro Ala Ala Cheese Pro Ala 450 455 460 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 465 470 475 480 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 485 490 495 Ala Pro Ala Ala Cheese Ala Pro Ala Cheese Ala Pro Ala Pro Ala Cheese 500 505 510 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 515 520 525 Ala Cheese Pro Ala Ala Pro Ala Pro Ala Cheese Pro Ala Ala Cheese Pro Ala 530 535 540 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 545 550 555 560 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 565 570 575 Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala 580 585 590 Ala Pro Ala Pro Ser Ala Pro Ala Ala Asp Ser Glu Ser Asp Cys Thr 595 600 605 Gly Ser Glu Pro Val Asp Ala Phe Gln Ala Phe Ser Glu Gly Lys Glu 610 615 620 Ala Tyr Val Leu Val Arg Ser Thr Asp Pro Lys Ala Arg Asp Cys Leu 625 630 635 640 Lys Gly Glu Pro Ala Gly Glu Lys Gln Asp Asn Thr Leu Pro Val Met 645 650 655 Met Thr Phe Lys Asn Gly Thr Asp Trp Ala Ser Thr Asp Trp Thr Phe 660 665 670 Thr Leu Asp Gly Ala Lys Val Thr Ala Thr Leu Gly Asn Leu Thr Gln 675 680 685 Asn Arg Glu Val Val Tyr Asp Ser Gln Ser His His Cys His Val Asp 690 695 700 Lys Val Glu Lys Glu Val Pro Asp Tyr Glu Met Trp Met Leu Asp Ala 705 710 715 720 Gly Gly Leu Glu Val Glu Val Glu Cys Cys Arg Gln Lys Leu Glu Glu 725 730 735 Leu Ala Ser Gly Arg Asn Gln Met Tyr Pro His Leu Lys Asp Cys 740 745 750 <210> 31 <211> 751 <212> PRT <213> artificial sequence <220> <223> PAS-L-nomacopan <400> 31 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 1 5 10 15 Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala 20 25 30 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 35 40 45 Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala 50 55 60 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 65 70 75 80 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 85 90 95 Ala Pro Ala Ala Cheese Ala Pro Ala Cheese Ala Pro Ala Pro Ala Cheese 100 105 110 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 115 120 125 Ala Cheese Pro Ala Ala Pro Ala Pro Ala Cheese Pro Ala Ala Cheese Pro Ala 130 135 140 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 145 150 155 160 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 165 170 175 Ala Pro Ala Ala Cheese Ala Pro Ala Cheese Ala Pro Ala Pro Ala Cheese 180 185 190 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 195 200 205 Ala Cheese Pro Ala Ala Pro Ala Pro Ala Cheese Pro Ala Ala Cheese Pro Ala 210 215 220 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 225 230 235 240 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 245 250 255 Ala Pro Ala Ala Cheese Ala Pro Ala Cheese Ala Pro Ala Pro Ala Cheese 260 265 270 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 275 280 285 Ala Cheese Pro Ala Ala Pro Ala Pro Ala Cheese Pro Ala Ala Cheese Pro Ala 290 295 300 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 305 310 315 320 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 325 330 335 Ala Pro Ala Ala Cheese Ala Pro Ala Cheese Ala Pro Ala Pro Ala Cheese 340 345 350 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 355 360 365 Ala Cheese Pro Ala Ala Pro Ala Pro Ala Cheese Pro Ala Ala Cheese Pro Ala 370 375 380 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 385 390 395 400 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 405 410 415 Ala Pro Ala Ala Cheese Ala Pro Ala Cheese Ala Pro Ala Pro Ala Cheese 420 425 430 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 435 440 445 Ala Cheese Pro Ala Ala Pro Ala Pro Ala Cheese Pro Ala Ala Cheese Pro Ala 450 455 460 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 465 470 475 480 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 485 490 495 Ala Pro Ala Ala Cheese Ala Pro Ala Cheese Ala Pro Ala Pro Ala Cheese 500 505 510 Ala Pro Ala Pro Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro 515 520 525 Ala Cheese Pro Ala Ala Pro Ala Pro Ala Cheese Pro Ala Ala Cheese Pro Ala 530 535 540 Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro Ser Ala Pro Ala 545 550 555 560 Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 565 570 575 Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala 580 585 590 Ala Pro Ala Pro Ser Ala Pro Ala Ala Asp Ser Glu Ser Asp Cys Thr 595 600 605 Gly Ser Glu Pro Val Asp Ala Phe Gln Ala Phe Ser Glu Gly Lys Glu 610 615 620 Ala Tyr Val Leu Val Arg Ser Thr Asp Pro Lys Ala Arg Asp Cys Leu 625 630 635 640 Lys Gly Glu Pro Asn Gly Glu Lys Gln Asp Asn Thr Leu Pro Val Met 645 650 655 Met Thr Phe Lys Asn Gly Thr Asp Trp Ala Ser Thr Asp Trp Thr Phe 660 665 670 Thr Leu Asp Gly Ala Lys Val Thr Ala Thr Leu Gly Asn Leu Thr Gln 675 680 685 Asn Arg Glu Val Val Tyr Asp Ser Gln Ser His His Cys His Val Asp 690 695 700 Lys Val Glu Lys Glu Val Pro Asp Tyr Glu Met Trp Gln Ser Asp Ala 705 710 715 720 Gly Ala Asp Ala Val Glu Val Glu Cys Cys Arg Gln Lys Leu Glu Glu 725 730 735 Leu Ala Ser Gly Arg Asn Gln Met Tyr Pro His Leu Lys Gly Cys 740 745 750 <210> 32 <211> 20 <212> PRT <213> Artificial sequence <220> <223> Interphotoreceptor retinoid binding protein (IRBP) <400> 32 Ser Gly Ile Pro Tyr Ile Ile Ser Tyr Leu His Pro Gly Asn Thr Ile 1 5 10 15 Leu His Val Asp 20
Claims
1. Use of an agent in the preparation of a medicament for treating or preventing a proliferative retinal disease in a subject, wherein the agent is: (i) a protein consisting of amino acids 1 to 168 or 19 to 168 of the amino acid sequence SEQ ID NO: 2; (ii) a protein consisting of SEQ ID NO:23; (iii) a fusion protein comprising (a) a protein consisting of amino acids 1 to 168 or 19 to 168 of the amino acid sequence SEQ ID NO: 2, and (b) a second sequence; or (iv) a fusion protein comprising (a) a protein consisting of SEQ ID NO: 23, and (b) a second sequence; wherein the protein or fusion protein binds to C5 to prevent complement C5 from being cleaved into complement C5a and complement C5b by convertase, and / or binds to LTB4; wherein the medicament is formulated for intravitreal administration; wherein the subject is a human; and The treatment or prevention comprises administering to the subject a therapeutically or prophylactically effective amount of the drug.
2. Use of an agent in the preparation of a medicament for treating or preventing a proliferative retinal disease in a subject, wherein the agent is: (i) a nucleic acid molecule encoding a protein consisting of amino acids 1 to 168 or 19 to 168 of the amino acid sequence SEQ ID NO: 2; (ii) a nucleic acid encoding a protein consisting of SEQ ID NO: 23; (iii) a nucleic acid encoding a fusion protein comprising (a) a protein consisting of amino acids 1 to 168 or 19 to 168 of the amino acid sequence SEQ ID NO: 2, and (b) a second sequence; or (iv) a nucleic acid encoding a fusion protein comprising (a) a protein consisting of SEQ ID NO: 23, and (b) a second sequence; wherein the protein or fusion protein binds to C5 to prevent complement C5 from being cleaved into complement C5a and complement C5b by convertase, and / or binds to LTB4; wherein the medicament is formulated for intravitreal administration; wherein the subject is a human; and The treatment or prevention comprises administering to the subject a therapeutically or prophylactically effective amount of the drug.
3. The use according to claim 1 or 2, wherein the proliferative retinal disease is selected from the group consisting of dry age-related macular degeneration, autoimmune uveitis, infectious uveitis, wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, optic neuritis, retinal vein occlusion and retinopathy of prematurity.
4. The use according to claim 1 or 2, wherein the proliferative retinal disease is geographic atrophy.
5. The use according to claim 1 or 2, wherein the proliferative retinal disease is choroidal neovascularization.
6. The use according to claim 1 or 2, wherein the proliferative retinal disease is glaucoma-related optic neuritis.
7. The use according to claim 1 or 2, wherein the proliferative retinal disease is dry age-related macular degeneration.
8. The use according to claim 1 or 2, wherein the second sequence is a PAS sequence.
9. The use according to claim 8, wherein the fusion protein comprises multiple copies of one of the following: ASPAAPAPASPAAPAPSAPA (SEQ ID NO: 15); AAPASPAPAAPSAPAPAAPS (SEQ ID NO: 16); APSSPSPSAPSSPSPASPSS (SEQ ID NO: 17), SAPSSPSPSAPSSPSPASPS (SEQ ID NO: 18), SSPSAPSPSSPASPSPSSPA (SEQ ID NO: 19), AASPAAPSAPPAAASPAAPSAPPA (SEQ ID NO: 20) and ASAAAAPAAASAAASAPSAAA (SEQ ID NO: 21).
10. The use according to claim 9, wherein the fusion protein comprises 20 to 30 copies of one of SEQ ID NOs: 15-21.
11. The use according to claim 9, wherein the fusion protein comprises 30 copies of one of SEQ ID NOs: 15-21.
12. The use according to claim 9, wherein the fusion protein comprises a PAS sequence consisting of 30 copies of SEQ ID NO:
15.
13. The use according to claim 8, wherein the fusion protein is composed of composition: SEQ ID NO:
30.
14. The use according to claim 8, wherein the fusion protein is composed of composition: SEQ ID NO:
31.
15. The use according to claim 1 or 2, wherein the treatment or prevention further comprises administering an additional agent for treating a proliferative retinal disease.
16. The use according to claim 15, wherein the additional agent for treating proliferative retinal disease is selected from anti-inflammatory drugs, immunomodulatory therapy drugs, biological response modifier drugs, anti-VEGF treatment and a second agent, and the second agent is a protein comprising amino acids 19 to 168 of the amino acid sequence SEQ ID NO: 2 or a functional equivalent of the protein.
17. The use according to claim 16, in: (a) the anti-inflammatory drug is a steroid, (b) the immunomodulatory therapy drug is selected from methotrexate, azathioprine or mycophenolate mofetil, (c) the biological response modifier is an anti-TNF agent, (d) the anti-VEGF therapy is an anti-VEGF-A antibody or fragment thereof, an anti-VEGF aptamer, or another anti-VEGF antagonist or (e) the second agent is a protein consisting of amino acids 1 to 168 or 19 to 168 of the amino acid sequence SEQ ID NO:
2.
18. Use according to claim 17, wherein the steroid is a corticosteroid.
19. The use according to claim 17, wherein the anti-TNF agent is an anti-TNFα antibody or a fragment thereof.
20. The use according to claim 19, wherein the anti-TNFα antibody is infliximab or adalimumab.
21. The use according to claim 17, wherein the anti-VEGF-A antibody is bevacizumab or ranibizumab.
22. The use according to claim 17, wherein the anti-VEGF aptamer is pegaptanib.
23. The use according to claim 17, wherein the other anti-VEGF antagonist is aflibercept.
